[Tika Wiki] Update of "cTAKESParser" by ChrisMattmann

[Apache Wiki]

Dear Wiki user,

You have subscribed to a wiki page or wiki category on "Tika Wiki" for change 
notification.

The "cTAKESParser" page has been changed by ChrisMattmann:
https://wiki.apache.org/tika/cTAKESParser?action=diff&rev1=4&rev2=5

Comment:
- finishing up the example

  You will need to place the CTAKESConfig.properties file in a classpath 
directory, e.g., org/apache/tika/parser/ctakes and include it on the classpath 
when calling the parser. Follow these steps:
  
   1. `mkdir -p $HOME/src/ctakes-config/org/apache/tika/parser/ctakes && cd 
$HOME/src/ctakes-config/org/apache/tika/parser/ctakes`
-  2. `curl -kO 
"https://issues.apache.org/jira/secure/attachment/12737116/CTAKESConfig.properties";'
+  2. `curl -kO 
"https://issues.apache.org/jira/secure/attachment/12737116/CTAKESConfig.properties"`
  
  = Setting up the Tika Config file =
  
@@ -94, +94 @@

  To download and set up the custom Tika config, do the following.
  
   1. `cd $HOME/src/ctakes-config`
-  2. `curl kO 
"here|https://issues.apache.org/jira/secure/attachment/12737115/tika-config.xml"`
+  2. `curl -kO 
"https://issues.apache.org/jira/secure/attachment/12737115/tika-config.xml"`
  
  = Putting it all together: Tika-App =
  
- With all of the above information set and provided, you can call the 
cTAKESParser in Tika. Below is an example of how to use it on a downloaded PDF 
file from PubMed. You can find an example PDF file 
[[here|http://onlinelibrary.wiley.com/doi/10.1002/ajh.23615/epdf]].
+ With all of the above information set and provided, you can call the 
cTAKESParser in Tika. Below is an example of how to use it on a downloaded PDF 
file from PubMed. You can find an example PDF file 
[[http://onlinelibrary.wiley.com/doi/10.1002/ajh.23615/epdf|here]].
  
  The cTAKES parser can then be invoked from tika-app as follows:
  
@@ -109, +109 @@

  Which will produce (after much printing and output):
  
  {{{
-  Content-Length: 457115
+ Content-Length: 457115
  Content-Type: application/pdf
  Creation-Date: 2013-11-20T13:24:11Z
  Last-Modified: 2013-11-22T14:13:25Z
@@ -1362, +1362 @@

  xmpTPg:NPages: 7
  }}}
  
+ = Will this work from Tika Server? =
+ 
+ Yes, it will! However it's a little tricky since cTAKES also includes its own 
version of Apache CXF and the jar version numbers are different than the 
version Tika Server uses, causing the classpath we generated before to fail 
(the one for tika-app). To obviate this, follow the below steps:
+ 
+ First, generate a script that will build us a classpath from 
`$CTAKES_HOME/lib` that doesn't include the cxf jar files. This would look 
something like this:
+ 
+ {{{
+ #!/bin/bash
+ 
+ CLASSPATH=""
+ for f in $(ls ${CTAKES_HOME}/lib/*.jar); do
+     if [[ $f != *"cxf"* ]]; then
+         CLASSPATH+=$f
+         CLASSPATH+=":"
+     fi
+ done
+ 
+ echo $CLASSPATH
+ }}}
+ 
+ Save this script as `gen-server-classpath.sh`. Then, start Tika-server like 
so:
+ 
+ {{{
+ java -classpath 
tika-server/target/tika-server-1.10-SNAPSHOT.jar:${CTAKES_HOME}/desc:${CTAKES_HOME}/resources::./config:`gen-server-classpath.sh`
 org.apache.tika.server.TikaServerCli --config tika-config.xml
+ }}}
+ 
+ With Tika server started, let's post that biomedical PDF file to it and see 
what happens!
+ 
+ {{{
+ curl -T Vose-2013-American_Journal_of_Hematology.pdf -H "Content-Disposition: 
attachment;filename=Vose-2013-American_Journal_of_Hematology.pdf" 
http://localhost:9998/rmeta
+ }}}
+ 
+ And the output should be:
+ 
+ {{{
+ [
+     {
+         "Content-Type": "application/pdf",
+         "Creation-Date": "2013-11-20T13:24:11Z",
+         "Last-Modified": "2013-11-22T14:13:25Z",
+         "Last-Save-Date": "2013-11-22T14:13:25Z",
+         "WPS-ARTICLEDOI": "10.1002/ajh.23615",
+         "WPS-JOURNALDOI": "10.1002/(ISSN)1096-8652",
+         "WPS-PROCLEVEL": "2",
+         "X-Parsed-By": [
+             "org.apache.tika.parser.CompositeParser",
+             "org.apache.tika.parser.ctakes.CTAKESParser",
+             "org.apache.tika.parser.DefaultParser",
+             "org.apache.tika.parser.pdf.PDFParser"
+         ],
+         "X-TIKA:content": 
"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nJW-AJH#130002
 1083..1088\n\n\nContinuing medical education activity\nin American Journal of 
Hematology\n\nCME Author: Julie M. Vose, M.D., M.B.A.\nCME Editor: Ayalew 
Tefferi, M.D.\n\nCME Information: Mantle Cell Lymphoma: 2013 Update 
on\nDiagnosis, Risk-Stratification andClinical Management\nIf you wish to 
receive credit for this activity, please refer\n\nto the website: 
www.wileyhealthlearning.com\n\nAccreditation and Designation 
Statement:\n\nBlackwell Futura Media Services is accredited by 
the\nAccreditation Council for Continuing Medical Education to\nprovide 
continuing medical education for physicians.\nBlackwell Futura Media Services 
designates this journal-\n\nbased CME for a maximum of 1 AMA PRA Category 
1\nCreditTM. Physicians should only claim credit commensu-\nrate with the 
extent of their participation in the activity.\n\nEducational 
Objectives\n\nUpon completion of this educational activity, participants\nwill 
be better able to:\n1. Identify the histologic types and prognostic 
models\n\nused for mantle cell lymphoma\n2. Explain the different options for 
initial therapy for man-\n\ntle cell lymphoma\n3. Explain the different options 
for treatment of recurrent\n\nmantle cell lymphoma\n\nActivity 
Disclosures\n\nNo commercial support has been accepted related to 
the\ndevelopment or publication of this activity.\nAuthor: Julie M. Vose, M.D., 
M.B.A., discloses research\n\ngrant support from Allos Therapeautics/Spectrum, 
Bristol-\nMyers Squibb, Celgene, Genentech, GlaxoSmithKline, Incyte\nCorp., 
Janssen Biotech, Millennium, Onyx Pharmaceuticals,\nPharmacyclics, 
Sanofi-Aventis US, Inc., and US Biotest, Inc.\nCME Editor: Ayalew Tefferi, M.D. 
has no conflicts of\n\ninterest to disclose.\nThis activity underwent peer 
review in line with the stand-\n\nards of editorial integrity and publication 
ethics maintained\nby American Journal of Hematology. The peer reviewers\nhave 
no conflicts of interest to disclose. The peer review\nprocess for American 
Journal of Hematology is single\n\nblinded. As such, the identities of the 
reviewers are not dis-\nclosed in line with the standard accepted practices of 
medi-\ncal journal peer review.\nConflicts of interest have been identified and 
resolved in\n\naccordance with Blackwell Futura Media Services’s Policy\non 
Activity Disclosure and Conflict of Interest. The primary\nresolution method 
used was peer review and review by a\nnon-conflicted expert.\n\nInstructions on 
Receiving Credit\n\nThis activity is intended for physicians. For 
information\non applicability and acceptance of continuing medical edu-\ncation 
credit for this activity, please consult your professio-\nnal licensing 
board.\nThis activity is designed to be completed within one\n\nhour; 
physicians should claim only those credits that reflect\nthe time actually 
spent in the activity. To successfully earn\ncredit, participants must complete 
the activity during the\nvalid credit period, which is up to two years from 
initial pub-\nlication. Additionally, up to 3 attempts and a score of 70%\nor 
better is needed to pass the post test.\nFollow these steps to earn 
credit:\n\n� Log on to www.wileyhealthlearning.com\n� Read the target audience, 
educational objectives, and\nactivity disclosures.\n\n� Read the activity 
contents in print or online format.\n� Reflect on the activity contents.\n� 
Access the CME Exam, and choose the best answer\nto each question.\n\n� 
Complete the required evaluation component of the\nactivity.\n\n� Claim your 
Certificate.\nThis activity will be available for CME credit for 
twelve\n\nmonths following its launch date. At that time, it will be\nreviewed 
and potentially updated and extended for an addi-\ntional twelve months.\n\nVC 
2013 Wiley Periodicals, Inc.\n\nAmerican Journal of Hematology 
http://wileyonlinelibrary.com/cgi-bin/jhome/351051082\n\n\n\n\n\nANNUAL 
CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES:\nA CONTINUING MEDICAL EDUCATION 
SERIES\n\nMantle cell lymphoma: 2013 Update on diagnosis,\nrisk-stratification, 
and clinical management\n\nJulie M. Vose*\n\nDisease Overview: Mantle cell 
lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement\nof the 
lymph nodes, spleen, blood, and bone marrow with a short remission duration to 
standard therapies\nand a median overall survival of 4–5 years.\nDiagnosis: 
Diagnosis is based on lymph node, bone marrow, or tissue morphology of 
centrocytic lympho-\ncytes, small cell type, or blastoid variant cells. A 
chromosomal translocation t(11:14) is the molecular hall-\nmark of MCL, 
resulting in the overexpression of cyclin D1. Cyclin D1 is detected by 
immunohistochemistry\nin 98% of cases. The absence of SOX-11 or a low Ki-67 may 
correlate with a more indolent form of MCL.\nThe differential diagnosis of MCL 
includes small lymphocytic lymphoma, marginal zone lymphoma, and fol-\nlicular 
lymphoma.\nRisk Stratification: The Mantle Cell Lymphoma International 
Prognostic Index (MIPI) is the prognostic\nmodel most often used and 
incorporates ECOG performance status, age, leukocyte count, and lactic 
dehy-\ndrogenase. A modification of the MIPI also adds the Ki-67 proliferative 
index if available. The median over-\nall survival (OS) for the low risk group 
was not reached (5-year OS of 60%). The median OS for the\nintermediate risk 
group was 51 months and 29 months for the high risk group.\nRisk-Adapted 
Therapy: For selected indolent, low MIPI MCL patients, initial observation may 
be appropriate\ntherapy. For younger patients with intermediate or high risk 
MIPI MCL, aggressive therapy with a cytarabine\ncontaining regimen6 autologous 
stem cell transplantation should be considered. For older MCL patients\nwith 
intermediate or high risk MIPI, combination chemotherapy with R-CHOP, 
R-Bendamustine, or a clinical\ntrial should be considered. At the time of 
relapse, agents directed at activated pathways in MCL cells such\nas bortezomib 
(NFkB inhibitor) or lenalidamide (anti-angiogenesis) are approved agents. 
Clinical trials with\nIbruitinib (Bruton’s Tyrosine Kinase inhibitor) or 
Idelalisib (PI3K inhibitor) have demonstrated excellent clin-\nical activity in 
MCL patients. Autologous or allogeneic stem cell transplantation can also be 
considered in\nyoung patients. Am. J. Hematol. 88:1083–1088, 2013. VC 2013 
Wiley Periodicals, Inc.\n\nDisease Overview\nMantle cell lymphoma (MCL) was 
originally identified in\n\nthe Kiel classification as a “centrocytic lymphoma” 
[1]. This\ntype of lymphoma was termed a lymphocytic lymphoma of\nintermediate 
differentiation by Berard and Dorfman [2]. A\ndistinct subtype of MCL was 
characterized by atypical small\nlymphoid cells with wide mantles around benign 
germinal\ncenters and was called a mantle zone lymphoma [3]. With\nthe advent 
of the revised European-American and the later\nWorld Health Organization 
classifications, MCL was made\na distinct lymphoma subtype and was termed an 
aggres-\nsive lymphoma [4,5]. MCL represents about 4% of all\nlymphomas in the 
US and 7–9% in Europe [6].\n\nPatients with MCL have a median age in their 60s 
and\nhave a striking male predominance (2:1). Patients generally\nhave stage 
III/IV disease and present with extensive lymph-\nadenopathy, blood and bone 
marrow involvement, and\nsplenomegaly [7]. Eighty percent of the patients with 
the\nmantle zone variant have splenomegaly which may be\nmassive. The MCL 
patients can present with pancytopenia\nor a leukemic presentation with 
extensive leukocytosis [8].\nSome degree of peripheral blood involvement can 
be\ndetected in most cases by flow cytometry [9]. Other extra-\nnodal sites 
include the gastrointestinal tract either in the\nstomach or colon, liver, or 
in Waldeyer’s ring [10]. Some\npatients have sheets of lymphomatous polyps of 
the large\nbowel, lymphomatous polyposis, which sometimes leads to\nthe 
diagnosis of MCL [11]. If random blind biopsies are\ndone of normal appearing 
mucosa of the colon in patients\n\nwho have been diagnosed with MCL in other 
locations, a\nlarge percentage are positive for MCL involvement [11].\nOther 
extranodal sites for MCL involvement include the\nskin, lacrimal glands, and 
central nervous system [10].\n\nDiagnosis\nThe diagnosis is made on a biopsy of 
a lymph node, tis-\n\nsue, bone marrow, or blood phenotype, which shows 
the\ntypical morphology of monomorphic small to medium sized\nlymphoid cells 
with irregular nuclear contours [5]. Four\ncytologic variants of MCL are 
recognized, including the\nsmall cell variant, mantle zone variant, diffuse 
variant, and\nthe blastic variant [12]. Immunophenotyping is commonly\nused 
with the MCL cells being CD201, CD51, and positive\nfor Cyclin D1, whereas 
being negative for CD10 and Bcl6\n[5]. The hallmark chromosomal translocation 
t(11:14)\n(q13;32) identifies MCL and can be shown in most cases\n\nDivision of 
Hematology/Oncology, University of Nebraska Medical Center,\nOmaha, 
Nebraska\n\nConflict of interest: Nothing to report.\n\n*Correspondence to: 
Julie M. Vose, Division of Hematology/Oncology, Uni-\nversity of Nebraska 
Medical Center, Omaha, NE 68198-7680. E-mail:\njmv...@unmc.edu\n\nReceived for 
publication 17 October 2013; Accepted 17 October 2013\n\nAm. J. Hematol. 
88:1083–1088, 2013.\n\nPublished online in Wiley Online Library 
(wileyonlinelibrary.com).\nDOI: 10.1002/ajh.23615\n\nVC 2013 Wiley Periodicals, 
Inc.\n\nAmerican Journal of Hematology 
http://wileyonlinelibrary.com/cgi-bin/jhome/351051083\n\nAJH Educational 
Material\n\n\n\n[13]. This translocation leads to the aberrant expression 
of\ncyclin D1, which is not typically expressed in normal lym-\nphocytes. A few 
cyclin D1 negative cases have been identi-\nfied and appear to have an 
overexpression of cyclin D2 or\nD3 instead [14]. Recently, overexpression of 
the transcrip-\ntion factor, SOX11, has been described as a diagnostic\nmarker 
for MCL with the absence of SOX11 a characteristic\nof indolent MCL [15]. 
Biologic features such as a high Ki-\n67 proliferation index or p53 mutations 
and p16 deletions\nare closely related to the more aggressive MCL 
subtypes\nsuch as the blastoid variants [16]. A model of 
molecular\npathogenesis and progression of MCL has been proposed\nby Jares et 
al. (Fig. 1) [17].\n\nStaging procedures should include a complete 
blood\ncount, chemistry profile, a lactic dehydrogenase (LDH), a\nbone marrow 
evaluation, with immunophenotyping by flow\ncytometry of the bone marrow and 
blood, and computed\ntomography of the chest, abdomen, and pelvis. There 
are\nlimited studies in using FDG-PET scanning for MCL, but it\nis often 
clinically useful. The standard uptake values of\nsites involved with MCL often 
have low or intermediate val-\nues [18]. Evaluation of the gastrointestinal 
tract with endos-\ncopy is warranted if there are clinical symptoms or if 
a\ndose intense regimen will be used. Evaluation of the cere-\nbral spinal 
fluid is not usually done unless there are neuro-\nlogic symptoms or if the 
patient has the blastoid variant\n[19]. The majority of patients have stage III 
or IV disease\nafter complete staging is completed.\n\nRisk Stratification\nThe 
International Prognostic Index (IPI) was first devel-\n\noped for patients with 
diffuse large B-cell non-Hodgkin lym-\nphoma [20]. This was used for patients 
with MLC but was\nnot very discriminatory, particularly for the lower 
risk\npatients. More recently, the first prognostic index for MCL,\nthe Mantle 
cell International Prognostic Index (MIPI), was\nformulated by the European MCL 
Network [21]. The inde-\npendent prognostic factors for shorter overall 
survival from\nthe MIPI were higher age, worse ECOG performance\n\nstatus, 
higher LDH, and a higher white blood cell count at\ndiagnosis. These were 
calculated as a continuous parame-\nter and three groups emerged: MIPI low-risk 
with the\nmedian overall survival not reached (5-yr OS 60%), MIPI\nintermediate 
risk with a median OS of 51 months, and a\nMIPI high risk group with a median 
OS of 29 months (Fig.\n2)[21]. This index has now been validated by other 
groups\n[22] (Table I).\n\nA simplified modification of the MIPI has also 
been\ndeveloped, which has high concordance to the original\nMIPI, but slightly 
less discriminatory power [21]. The addi-\ntion of the Ki-67 proliferation 
index also provides some\nadditional discriminatory power [21] (Table 
II).\n\nFor each prognostic factor, 0 to 3 points are given and\nthe points are 
summed up to a maximum of 11. Patients\nwith 0–3 points are low risk, patients 
with 4–5 points are\nintermediate risk, and patients with 6–11 points are 
high\nrisk. These risk categories correspond to the categories of\nthe original 
MIPI [21].\n\nFigure 1. A proposed model of molecular pathogenesis and 
progression of MCL (Reproduced from Ref. 17, with permission from [Nat Rev 
Cancer]). [Color figure can\nbe viewed in the online issue, which is available 
at wileyonlinelibrary.com.]\n\nFigure 2. Overall survival for low, 
intermediate, and high risk MCL according to\nthe MIPI classification 
(Reproduced from Ref. 21], with permission from [Blood])\n\nannual clinical 
updates in hematological malignancies: a continuing medical education 
series\n\n1084 American Journal of Hematology\n\n\n\n\nGene expression 
profiling has been performed on a large\nseries of MCL patients to evaluate a 
molecular predictor\nconsisting of 20 proliferation associated genes [23]. 
How-\never, a microarray-based technique is not feasible on a\nwide scale. 
Therefore, further testing of a minimum number\nof genes by formalin-fixed, 
paraffin-embedded tissue speci-\nmens has been studied [24]. This study 
identified five\ngenes including RAN, MYC, TNFRSF10B, POLE2, and\nSLC29A2 which 
were validated by a quantitative reverse-\ntranscriptase polymerase chain 
reaction (qRT-PCR) based\ntest and predicted survival in 73 patients with MCL. 
Further\nvalidation of these genes and technique is needed before\nthis is used 
outside a research context.\n\nRisk-Adapted Therapy\nMCL is responsive to a 
variety of initial therapies, but rel-\n\natively short-term remissions are 
achieved with conven-\ntional chemotherapy regimens. The median duration 
of\nremission in most trials is 1.5–3 years, and the median OS\nis 3–6 years 
with standard chemotherapy. However, there\nis a wide variation in outcomes 
with some patients having a\nvery aggressive presentation and succumbing to 
their dis-\nease in a short period of time, while other patients at 
the\nopposite end of the spectrum have a very indolent clinical\ncourse. 
Because of the rarity of MCL, most trials have not\nbeen large randomized 
trials, and much of the available\ninformation is based on smaller phase II 
trials with histori-\ncal controls.\n\nInitial management of asymptomatic low 
MIPI or\nelderly MCL patients\n\nGiven the unfavorable prognosis and the fact 
that stand-\nard therapy does not appear to cure patients with MCL, a\n“watch 
and wait” strategy for patients with asymptomatic,\nlow MIPI or elderly MCL 
patients should be considered.\nThis strategy would be similar to that used for 
asymptom-\natic patients with follicular or other indolent lymphomas. In\na 
study from Weill-Cornell Medical Center, 97 patients with\nMCL were evaluated 
[25]. Of the 97, 31 (32%) were\nobserved at the time of initial evaluation. 
These MCL\npatients were 46% low-MIPI index when compared to 32%\nlow-MIPI in 
the patients who received initial treatment. The\nmedian time to treatment for 
the observation group was 12\nmonths (range 4 to 128 months) [25]. When this 
observa-\ntional patient group needed treatment, the majority 
received\ncyclophosphamide, doxorubicin, oncovin, and prednisone\n(CHOP)—like 
treatment (55%), with some patients receiv-\ning rituximab monotherapy (13%), 
and at the time of publi-\ncation five patients had never received any therapy 
[25].\n\nWhen the asymptomatic elderly MCL patient population\ndoes become 
symptomatic and requires therapy, a number\n\nof options are available for 
treatment. Probably, the most\ncommonly used regimen in the past has been 
an\nanthracycline-based therapy such as CHOP [26]. Rituximab\nmonotherapy has 
some modest activity in MCL [27]. More\nrecently, rituximab has been added to 
the drugs in CHOP\n(R-CHOP) and tested in MCL. The first report of R-CHOP\nfor 
the treatment of MCL was in 40 previously untreated\npatients and yielded an 
overall response rate (ORR) of\n96%, including a complete response (CR) of 48% 
[28].\nDespite 36% of the patients having a molecular CR, there\nwas no 
difference in the median progression-free survival\n(PFS) between the patients 
who achieved a molecular CR\n(16.5 months) and those who did not (18.8 months) 
[28].\nThere were similar results from a randomized study in the\nGerman 
lymphoma study group which compared front-line\nCHOP to R-CHOP. In this study, 
the addition of rituximab\nto CHOP improved the ORR (94% vs. 75%, 
P50.0054)\nand the CR rate (34% vs. 7%, P50.00024) [29]. However,\nthis did not 
translate into significant improvements in PFS\nor OS in this study 
[29].\n\nPurine analogues have also been used for the treatment\nof MCL in the 
older patient population. Single agent fludar-\nabine demonstrated an ORR< 40%; 
however, when com-\nbined with cyclophosphamide and rituximab the 
response\nrate is closer to 60% [30,31]. More recently, a large\nrandomized 
trial done in Germany demonstrated that\nR-CHOP was superior to R-FC in the 
older MCL patient\npopulation with a 4 year OS of 65% for R-CHOP and 50%\nfor 
R-FC (P5 0.0032) [32]. In addition, a second random-\nization was done for 
maintenance either with rituximab or\ninterferon. The arm that produced the 
best PFS and OS,\nwas R-CHOP followed by rituximab maintenance with a\n4-year 
OS of 87% [32]. This is the first large randomized\ntrial which demonstrated a 
benefit for rituximab mainte-\nnance in PFS for patients with MCL.\n\nAnother 
agent that has been tested in patients with MCL,\nwhich demonstrated good 
activity is Bendamustine. A\nrandomized trial done in Europe compared R-CHOP 
to\nR-Bendamustine in a number of different lymphomas [33].\nIn this trial, the 
patients with MCL had a similar ORR (89%\nfor BR and 95% for R-CHOP). The BR 
regimen was asso-\nciated with a lower progression rate 42% vs. 63% for 
the\nR-CHOP arm [33]. In addition, the hematologic toxicity and\nalopecia were 
less in the R-Bendamustine arm [33]. A sec-\nond study evaluating R-CHOP vs. 
R-Bendamustine did not\ndemonstrate a superior outcome for the 
R-Bendamustine\nbut did demonstrate an equivalent outcome [34]\nSome clinical 
studies are testing agents used in relapsed\nMCL in combinations in the 
front-line setting such as\nR-CHOP1Bortezomib [35].\nRecommendations: 
Asymptomatic elderly or low-\nMIPI patients can be observed without any 
therapy.\nWhen the patients become symptomatic, first line therapy\nchoices 
include R-CHOP (6 rituximab maintenance), R-\nBendamustine, or a clinical 
trial.\n\nInitial management of a young symptomatic patient\nSeveral studies 
have suggested that aggressive thera-\n\npies in younger patients with MCL may 
improve the out-\ncomes. One of the first studies to evaluate this was 
the\nEuropean MCL Network study where responding patients\nunder age 65 years 
were randomized after induction ther-\napy to receive either myeloablative 
radio-chemotherapy fol-\nlowed by autologous stem cell transplantation (ASCT) 
or\nmaintenance interferon [36]. In this study, the patients in\nthe ASCT arm 
had an improved PFS over those in the\ninterferon arm [36]. Several other 
single arm and retrospec-\ntive studies have suggested patients receiving an 
induction\nregimen that contains high-dose cytarabine, such as\n\nTABLE I. The 
Original MIPI Score Calculations\n\n[0.0335 3 age in (years)] 3 age (years)\n1 
0.6978 (if ECOG performance status>1)\n1 1.367 3 log10 (LDH/ULN LDH)\n1 0.9393 
3 log10 (white blood cells per 10\n\n6 L)\n\nTABLE II. Simplified MIPI 
Index\n\nPoints Age, years ECOG PS LDH/ULN LDH WBC, 109/L\n\n0 <50 0–1 < 0.67 
<6.700\n1 50–59 – 0.67–0.99 6.700–9.999\n2 60–69 2–4 1.00–1.49 1.0–14.999\n3 
�70 – �1.500 �15.000\n\nannual clinical updates in hematological malignancies: 
a continuing medical education series\n\nAmerican Journal of Hematology 
1085\n\n\n\nhyperfractioned cyclophosphamide, vincristine, doxorubicin,\nand 
dexamethasone alternating with high-dose cytarabine\nand methotrexate 
(HyperCVAD 6rituximab) experience\nimproved survival [37–39].\n\nThe addition 
to rituximab to 6–8 cycles of HyperCVAD\nalternating with high dose cytarabine 
and methotrexate\nyielded a CR rate of 87% and had a 7-year failure-free 
sur-\nvival rate of 52% and OS of 68% [37]. This regimen was\ntested in a 
multicenter trial and was found to have a similar\nORR of 88% and CR rate of 
58%; however, there was\ngrade IV hematologic toxicity in 87% of the patients 
making\nthis regimen difficult to give in some community settings\n[38]. It was 
also suggested in a retrospective study that\npatients receiving R-HyperCVAD as 
an induction with auto\nASCT in CR1 had an improved outcome as compared 
to\nR-CHOP [39]. However, a further analysis of a separate\ncohort of MCL 
patients demonstrated that when corrected\nfor the MIPI, the outcomes may be 
similar [40].\n\nBecause the R-HyperCVAD alternating with 
methotrex-\nate/cytarabine is difficult to administer, modifications 
which\ndrop the methotrexate portion [41] or drop both the metho-\ntrexate and 
cytarabine have been tested [42]. In the study\nfrom Geisler et al. [41], 160 
younger MCL patients received\nrituximab1maxi-CHOP, alternating with rituximab1 
cytara-\nbine. Responders received high-dose chemotherapy with\nASCT. The 
6-year PFS was 66% and the OS was 70%.\nCompared to a historical control 
without the cytarabine, the\nresults were much improved with the regimen as 
outlined\n[41]. In a small pilot trial in an older population, the 
rituxi-\nmab–Hyper CVAD regimen without the methotrexate or\ncytarabine, but 
with maintenance rituximab demonstrated\nan ORR of 77% and a median PFS of 37 
months [42].\nAnother approach has been for patients to receive R-\nCHOP X 3 
cycles, then Rituximab, cisplatin, cytarabine,\ndexamethasone (R-DHAP) X 3, 
followed by high dose\nchemotherapy and autologous stem cell 
transplantation\n[43]. This study also demonstrated an excellent 
5-year\noverall survival of 75% [43].\n\nThe role of autologous stem cell 
transplantation in CR1\nhas not been tested in a randomized trial. However in a 
ret-\nrospective analysis of 167 MCL patients under age 65, the\npatients 
received either R-HyperCVAD or R-CHOP followed\nby an auto ASCT in CR1 had an 
improved PFS compared\nto R-CHOP alone (P< 0.004), even when corrected 
for\nprognostic factors. [44]. The best induction regimen before\ntransplant 
has not been defined but is currently being eval-\nuated in clinical 
trials.\nRecommendations: For young symptomatic patients with\nMCL, 
considerations include R-HyperCVAD with high-dose\ncytarabine (6Methotrexate) 
followed by ASCT in CR1 for\nselected patients. For patients who are not 
candidates for\nstandard R-HyperCVAD with high dose cytarabine/metho-\ntrexate, 
possible alternatives include R-CHOP or\nR-Bendamustine. If possible, ASCT in 
CR1 should still be\nconsidered for these patients as well.\n\nManagement of 
relapse/refractory MCL\nFor patients with relapsed but asymptomatic MCL, 
fur-\n\nther “watch and wait” maybe possible as there are a per-\ncentage of 
patients with indolent MCL who may not need\ntherapy for months or years. Once 
the patient becomes\nsymptomatic many options are considerations. The 
Benda-\nmustine1 rituximab (BR) regimen has also been tested in\nrelapsed MCL 
patients. A phase II study of BR in 63\npatients with relapsed/refractory MCL 
demonstrated an\nORR or 90% with a CR of 60% and a median PFS of 30\nmonths 
[45].\n\nBecause many standard lymphoma salvage regimens\nhave limited activity 
in MCL, novel treatment approaches\n\nbased on targeting known signaling 
pathways have been\ntested. The first such agent to be tested as a 
proteasome\ninhibitor, bortezomib. As a monotherapy, bortezomib 
has\ndemonstrated ORRs in the 30–40% range [46]. In a large\nphase II study of 
141 evaluable MCL patients treated with\nbortezomib, there was an ORR of 33% 
with a CR rate of\n8% [47]. With further follow up, the phase II study of 
borte-\nzomib demonstrated a median time to progression of 6.7\nmonths and a 
median OS of 23.5 months [48]. Bortezomib\nhas also been combined with other 
agents such as Benda-\nmustine and rituximab in the BVR regimen which also 
had\nexcellent activity. In patients with MCL, the ORR rate for\nthe BVR 
regimen was 71% [49].\n\nThe PI3Kinase/Akt/mTOR pathway is implicated in 
the\npathogenesis of MCL [50]. Based upon this information the\nmTOR inhibitor, 
temsirolimus was tested in a phase II study\nof patients with 
relapsed/refractory MCL. In this study, tem-\nsirolimus demonstrated moderate 
activity with an ORR of\n44% [51]. In a phase III study of 162 
relapsed/refractory\npatients with MCL, high doses of temsirolimus (175 
mg/75\nmg) resulted in an ORR of 22% and a PFS of 4.8 months\n[52]. Other mTOR 
inhibitors, such as everolimus, have also\ndemonstrated activity in MCL 
[53].\n\nThe immunomodulatory agent lenalidomide has also\nshown promising 
activity against MCL. In a phase II study,\nZinzani et al. [54] reported an ORR 
of 41% in 39 MCL\npatients treated with lenalidomide. The larger EMERGE\ntrial 
tested single agent lenalidomide in 134 patients with\nrelapsed MCL. The ORR 
was 28% with a 7.5% CR rate\n[55]. There studies led to the FDA approval of 
lenalidomide\nfor patients with relapsed MCL who had failed 
bortezomib.\nLenalidomide has also been combined with rituximab with\npromising 
results. In a study by Wang et al. [56], 52\npatients with recurrent MCL were 
treated with lenalidamide\nand rituximab for recurrent disease. In this study, 
the ORR\nwas 58% and the CR rate was 33% with the combination\nbeing well 
tolerated.\n\nOther agents that appear to have activity in MCL include\nthe 
brutons tyrosine kinase (BTK) inhibitor (PCI-32765,\nIbruitinib) and PI3Kinase 
inhibitor (GS-1101, Idelalisib)\nwhich target the B-cell receptor pathways. In 
a study of 51\nMCL patients, the BTK inhibitor was reported to have a\n69% ORR 
and a CR rate of 16%, with no differences\nbetween bortezomib na€ıve and 
patients who had relapsed\nafter receiving bortezomib [57]. Kahl et al. 
reported on 38\npatients with MCL who were treated with Idelalisib 
who\ndemonstrated a 48% ORR [58].\n\nThere is not much data available for 
standard involved\nfield irradiation in MCL. However, there is data with the 
use\nof radioimmunotherapy (RIT) with Yttrium 90—Ibritumomab\nTiuxetan in 
patients with relapsed MCL demonstrating an\nORR of 31% [59]. When RIT is used 
to consolidate after\nimmunochemotherapy, it resulted in improvement of 
the\npercentages of responses compared with historical controls\n[60].\n\nThe 
use of high-dose chemotherapy and ASCT for\npatients with relapsed MCL has not 
demonstrated as prom-\nising results as with front-line use. However, a resent 
analy-\nsis of the CIBMTR data demonstrated in 159 MCL patients\nreceiving an 
autologous transplant for relapsed disease,\nthe 5-year OS was 44% and for 99 
patients receiving an\nallogeneic transplant for MCL, the 5-year OS was 
32%\n[61]. In appropriate patients with relapsed MCL who had a\nlong initial 
remission and have been successfully salvaged,\nASCT in CR2 maybe a 
consideration. Allogeneic stem cell\ntransplantation is felt to be the only 
potentially curative\ntreatment for advanced MCL. A number of small 
studies\nusing various reduced intensity preparative regimens with\nan 
allogeneic source of stem cell have been reported\n\nannual clinical updates in 
hematological malignancies: a continuing medical education series\n\n1086 
American Journal of Hematology\n\n\n\n[62,63]. In a study by Tam et al. [62], 
35 patients with\nrelapsed MCL receiving a reduced intensity regimen with\nan 
allogeneic stem cell transplant. With a median follow up\nof 56 months, the 
6-year PFS was 46% and the 6-year\nactuarial OS was 53% [62]. Although the 
relapse rates are\nless with allogeneic transplantation, the risks of 
graft-\nversus host disease and infectious complications are much\nhigher 
resulting in similar short term but apparently\nimproved long term results 
compared to autologous stem\ncell transplantation for relapsed 
MCL.\nRecommendations: My first choice for a relapsed MCL\npatient would be 
bendamustine/rituximab if the patient has\nnot previously received 
bendamustine. Other options would\ninclude a bortezomib containing regimen or 
lenalidamide. If\nthe patient is a candidate for stem cell transplantation, 
con-\nsideration for an autologous transplant if there was a long\nfirst 
remission or a reduced intensity allogeneic stem cell\ntransplant should be 
given. When clinically available, B-cell\nreceptor pathway inhibitors would be 
an excellent choice\nfor therapy as well.\n\nReferences\n1. Gerard-Marchant R, 
Hamlin I, Lennert K, et al. Classification of non-Hodgkin’s\n\nlymphomas 
[letter]. Lancet 1974;2:405–408.\n\n2. Berard CW, Dorfman RF. Histopathology of 
malignant lymphomas. Clin Hae-\nmatol 1974;3:39–45.\n\n3. Weisenburger DD, Kim 
H, Rappaport H. Mantle-zone lymphoma. A follicular\nvariant of intermediate 
lymphocytic lymphoma. Cancer 1982;49:1429–1434.\n\n4. Harris NL, Jaffe ES, 
Stein H, et al. A revised European-American classification\nof lymphoid 
neoplasms: A proposal from the International Lymphoma Study\nGroup. Blood 
1994;84:1361–1392.\n\n5. Swerdlow SH, Campo E, Harris N, et al. WHO 
Classification of Tumors of the\nHaematopietic and Lymphoid Tissues. Lyon, 
France: IARC; 2008.\n\n6. Non-Hodgkin’s Lymphoma Classification project. A 
clinical evaluation of the\nInternational Lymphoma Study Group. Blood 
1997;89:3909–3918.\n\n7. Tiemann M, Schrader C, Klapper W, et al. 
Histopathology, cell proliferation\nindices and clinical outcome in 304 
patients with mantle cell lymphoma (MCL):\n\nA clinicopathological study from 
the European MCL Network. Br J Haematol\n2005;131:29–38.\n\n8. Ferrer A, 
Salaverria I, Bosch F, et al. Leukemic involvement is a common fea-\nture in 
mantle cell lymphoma. Cancer 2007;109:2473–2480.\n\n9. Ghielmini M, Zucca E. 
How I treat mantle cell lymphoma. Blood 2009;114:\n1469–1476.\n\n10. Samaha H, 
Dumontet C, Ketterer N, et al. Mantle cell lymphoma: A retrospec-\ntive study 
of 121 cases. Leukemia 1998;34:329–336.\n\n11. Romaguera JE, Medeiros LJ, 
Hagemeister FB, et al. Frequency of gastrointes-\ntinal involvement and its 
clinical significance in mantle cell lymphoma. Cancer\n2003;97:586–591.\n\n12. 
Bertoni R, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J 
Bio-\nchem Cell Biol 2007;39:1747–1753.\n\n13. Bertoni F, Rinaldi A, Zucca E, 
Cavalli F. Update on the molecular biology of\nmantle cell lymphoma. Hematol 
Oncol 2006;24:22–27.\n\n14. Rosenwald A, Wright G, Wiestner A, et al. The 
proliferation gene expression\nsignature is a quantitative integrator of 
oncogenic events that predicts survival\nin mantle cell lymphoma. Cancer Cell 
2003;3:185–197.\n\n15. Fernandez V, Salamero O, Espinet B, et al. Genomic and 
gene expression\nprofiling defines indolent forms of mantle cell lymphoma. 
Cancer Res 2010;70:\n1408–1418.\n\n16. Bernard M, Gressin R, Lefrere F, et al. 
Blastic variant of mantle cell lym-\nphoma: A rare but highly aggressive 
subtype. Leukemia 2001;15:1785–1791.\n\n17. Jares P, Colomer D, Campo E. 
Genetic and molecular pathogenesis of mantle\ncell lymphoma: Perspectives for 
new targeted therapeutics. Nat Rev Cancer\n2007;7:750–762.\n\n18. Gill S, Wolf 
M, Prince HM, et al. [18F] fluorodeoxyglucose positron emission\ntomography 
scanning for staging, response assessment, and disease surveil-\nlance in 
patients with mantle cell lymphoma. Clin Lymphoma Myeloma 
2008;8:\n159–165.\n\n19. Ferrer A, Bosch F, Villamor N, et al. Central nervous 
system involvement in\nmantle cell lymphoma. Ann Onc 2008;19:135–141.\n\n20. 
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A 
predic-\ntive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 
1993;329:\n987–994.\n\n21. Hoster E, Dreyling M, Klapper W, et al. A new 
prognostic index (MIPI) for\npatients with advanced mantle cell lymphoma. Blood 
2008;111:558–565.\n\n22. Geisler CH, Kolstad A, Laurell A, et al. The mantle 
cell lymphoma International\n\nPrognostic Index (MIPI) is superior to the 
International Prognostic Index (IPI)\nin predicting survival following 
intensive first line immunochemotherapy and\nautologous stem cell 
transplantation (ASCT). Blood 2010;115:1530–1533.\n\n23. Rosenwald A, Wright G, 
Wiestner A, et al. The proliferation gene expression\nsignature is a 
quantitative integrator of oncogenic events that predicts survival\nin mantle 
cell lymphoma. Cancer Cell 2003;3:185–197.\n\n24. Hartmann E, Fernandez V, 
Moreno V, et al. Five-gene model to predict sur-\nvival in mantle-cell lymphoma 
using frozen or formalin-fixed, paraffin-embed-\nded tissue. J Clin Onc 
2008;26:4966–4972.\n\n25. Martin P, Chadburn A, Christos P, et al. Outcome of 
deferred initial therapy in\n\nmantle-cell lymphoma. J Clin Onc 
2009;27:1209–1213.\n\n26. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle 
cell lymphoma: A clini-\ncopathologic study of 68 cases from the Nebraska 
Lymphoma Study Group.\nAm J Hematol 2000;64:190–196.\n\n27. Foran JM, Rohatiner 
AZ, Cunningham D, et al. European phase II study of rit-\nuximab (chimeric 
anti-CD20 monoclonal antibody) for patients with newly diag-\nnosed mantle-cell 
lymphoma and previously treated mantle-cell lymphoma,\nimmunocytoma, and small 
B-cell lymphocytic lymphoma. J Clin Onc 2000;18:\n317–324.\n\n28. Howard OM, 
Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction\ntherapy for newly 
diagnosed mantle-cell lymphoma: Molecular complete\nresponses are not 
predictive of progression-free survival. J Clin Onc 2002;20:\n1288–1294.\n\n29. 
Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab 
and\ncyclophosphamide, doxorubicin, vincristine, and prednisone 
significantly\nimproves response and time to treatment failure, but not long 
term outcome in\npatients with previously untreated mantle cell lymphoma: 
Results of a prospec-\ntive randomized trial of the German Low Grade Lymphoma 
Study Group\n(GLSG). J Clin Onc 2005;23:1984–1992.\n\n30. Foran JM, Rohatiner 
AZ, Coiffier B, et al. Multicenter phase II study of fludara-\nbine phosphate 
for patients with newly diagnosed lymphplasmacytoid lym-\nphoma, Waldenstrom’s 
macroglobulinemia, and mantle cell lymphoma. J Clin\nOncol 
1999;17:546–553.\n\n31. Cohen BJ, Moskowitz C, Straus D, et al. 
Cyclophsphamide/fludarabine (CF) is\nactive in the treatment of mantle cell 
lymphoma. Leuk Lymphoma 2001;42:\n1015–1022.\n\n32. Kluin-Nelemans JC, Hoster 
E, Hermine O, et al. Treatment of older patients\n\nwith mantle cell lymphoma. 
NEJM 2012;376:520–531.\n\n33. Rummel M, Niederle N, Maschmeyer G, et al. 
Bendamustine plus rituximab\nversus CHOP plus rituximab as first-line treatment 
for patients with indolent\nand mantle-cell lymphomas: An open-label, 
muticentre, randomised, phase 3\nnon-inferiority trial. Lancet 
2013;381:1203–1210.\n\n34. Flinn IW, Van der Jagt RH, Kahl BS, et al. An 
open-level, randomized study of\nbendamustine and rituximab (BR) compared with 
rituximab, cyclophospha-\nmide, vincristine, and prednisone (R-CVP) or 
rituximab, cyclophosphamide,\ndoxorubicin, vincristine, and prednisone (R-CHOP) 
in first-line treatment of\npatients with advanced indolent non-Hodgkin’s 
lymphoma (NHL) or mantle cell\n\nlymphoma (MCL): The Bright Study. Blood 
2012;121:902a.\n\n35. Ruan J, Martin P, Furman RR, et al. Bortezomib plus 
CHOP-Rituximab for pre-\nviously untreated diffuse large B-cell lymphoma and 
mantle cell lymphoma.\nJ Clin Onc 2010;29:690–697.\n\n36. Dreyling M, Lenz G, 
Hoster E, et al. Early consolidation by myeloablative\nradiochemotherapy 
followed by autologous stem cell transplantation in first\nremission 
significantly prolongs progression-free survival in mantle cell lym-\nphoma: 
Results of a prospective randomized trial of the European MCL Net-\nwork. Blood 
2005;105:2677–2684.\n\n37. Romaguera JE, Fayad L, Rodriguez MA, et al. High 
rate of durable remission\nafter treatment of newly diagnosed aggressive 
mantle-cell lymphoma with rit-\nuximab plus HyperCVAD Alternating with 
Rituximab plus high-dose methotrex-\nate and cytarabine. J Clin Onc 
2005;23:7013–7023.\n\n38. Bernstein SH, Epner E, Unger JM, et al. A phase II 
multicenter trial of Hyper-\nCVAD MTX/Ara-C and rituximab in patients with 
previously untreated mantle\ncell lymphoma: SWOG 0213. Ann Onc 
2013;24:1587–1593.\n\n39. Vose J, Loberiza F, Bierman P, et al. Mantle cell 
lymphoma (MCL): Induction\ntherapy with HyperCVAD/high dose methotrexate and 
cytarabine (MC) 1/2 rit-\nuximab improves results of autologous stem cell 
transplant in first remission.\nJ Clin Onc 2006;24:424a.\n\n40. Budde LE, 
Guthrie KA, Till GB, et al. Mantel cell lymphoma International Prog-\nnostic 
Index but not pretransplantation induction regimen predicts survival 
for\n\npatients with mantle-cell lymphoma receiving high-dose therapy and 
autolo-\ngous stem cell transplantation. J Clin Oncol 2011;29:3023–3029.\n\n41. 
Giesler CH, Kolstad A, Lurell A, et al. Long-term progression-free survival 
of\nmantle cell lymphoma after intensive front-line immunochemotherapy with 
in\nvivo-purged stem cell rescue: A non-randomized phase 2 multicenter study 
by\n\nthe Nordic Lymphoma Group. Blood 2008;112:2687–2693.\n\n42. Kahl BS, 
Longo WL, Eickhoff JC, et al. Maintenance rituximab following induc-\ntion 
chemoimmunotherapy may prolong progression-free survival in mantle\ncell 
lymphoma: A pilot study from the Wisconsin Oncology Network. Ann\nOncol 
2006;17:1418–1423.\n\n43. Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP 
plus rituximab fol-\nlowed by autologous stem cell transplantation in mantle 
cell lymphoma: A\nphase 2 study from the Groupe d’Etude des Lymphomes de 
l’Adulte. Blood\n2013;121:48–53.\n\n44. LeCase AS, Vandergrift JL, Rodriguez 
MA, et al. Comparative outcome of ini-\ntial therapy for younger patients with 
mantle cell lymphoma: An analysis form\nthe NCCN NHL Database. Blood 
2012;119:093–2099.\n\n45. Rummel M, Atta J, Welslau M. Bendamustine and 
rituximab (BR) are effective\nand has a favorable toxicity profile in the 
treatment of mantle cell and low-\ngrade non-Hodgkin’s lymphoma. J Clin Onc 
2005;23:3383–3389.\n\nannual clinical updates in hematological malignancies: a 
continuing medical education series\n\nAmerican Journal of Hematology 
1087\n\n\n\n46. O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical 
experience with the\nnovel proteasome inhibitor bortezomib in patients with 
indolent non-Hodgkin’s\nlymphoma and mantle cell lymphoma. J Clin Oncol 
2005;23:676–684.\n\n47. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter 
phase II study of bortezo-\nmib in patients with relapsed or refractory mantle 
cell lymphoma. J Clin Oncol\n2006;24:4867–4874.\n\n48. Goy A, Bernstein SH, 
Kahl BS, et al. Bortezomib in patients with relapsed or\nrefractory mantle cell 
lymphoma: Updated time-to-event analyses of the multi-\ncenter phase 2 PINNACLE 
study. Ann Onc 2009;20:520–525.\n\n49. Friedberg JW, Vose JM, Kelly JL, et al. 
The combination of bendamustine, bor-\ntezomib, and rituximab for patients with 
relapsed/refractory indolent and man-\ntle cell lymphoma. Blood 
2011;117:2807–2812.\n\n50. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell 
lymphoma: Biology, patho-\ngenesis, and the molecular basis of treatment in the 
genomic era. Blood 2011;\n117:26–38.\n\n51. Ansell SM, Inwards DJ, Rowland KM, 
et al. Low-dose single-agent temsiroli-\nmus for relapsed mantle cell lymphoma: 
A phase 2 trial in the North Central\nCancer Treatment Group. Cancer 
2008;113:508–514.\n\n52. Hess G, Herbrecht R, Romaguera J, et al. Phase III 
study to evaluate temsiro-\nlimus compared with investigator’s choice therapy 
for the treatment of relapsed\nor refractory mantle cell lymphoma. J Clin Oncol 
2009;27:3822–3829.\n\n53. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II 
trial of the oral mTOR\ninhibitor everoliumus in relapsed aggressive lymphoma. 
Leukemia 2011;25:\n341–347.\n\n54. Zinzani PL, Witzig TE, Vose J, et al. 
Confirmation of the efficacy and safety of lenali-\ndomide oral monotherapy in 
patients with relapsed or refractory mantle cell lym-\nphoma: Results of an 
international study (NHL-003). Blood 2008;112:262–267.\n\n55. Goy A, Sinha R, 
Williams ME, et al. Single-agent lenalidomide in patients\nwith mangle-cell 
lymphoma who relapsed or progressed after or were\nrefractory to bortezomib: 
Phase II MCL-001 (EMERGE) Study. J Clin Onc\n2013;49:2835.\n\n56. Wang M, Fayad 
L, Wagner-Bartak N, et al. Lenalidamide in combination with\nrituximab for 
patients with relapsed or refractory mantle-cell lymphoma: A\n\nphase 1/2 
clinical trial. Lancet Oncol 2012;13:716–723.\n57. Wang L, Rule S, Martin P, et 
al. Targeting BTK with Ibruitinib in relapsed or\n\nrefractory mantle cell 
lymphoma. NEJM 2013;369:507–516.\n58. Kahl B, Byrd J, Flinn I, et al. 
Significant clinical activity of CAL-101, an isoform\n\nselective inhibitor of 
phosphatidylinositol 3 kinase P110D, in patients with relapsed\nor refractory 
indolent and mantle cell lymphoma. Ann Onc 2011;22:350a.\n\n59. Wang M, Oki Y, 
Pro B, et al. Phase II study of Yttrium-90 Ibritumomab tiuxetan\nin patients 
with relapsed or refractory mantle cell lymphoma. J Clin 
Oncol\n2009;27:5213–5218.\n\n60. Smith MR, Linjun A, Gordon LI, et al. Phase II 
study of rituximab plus cyclophos-\nphamide, doxorubicin, vincristine, and 
prednisone immunochemotherapy fol-\nlowed by 90Y-Ibritumomab tiuxetan in 
untreated mantle cell lymphoma: Eastern\nCooperative Oncology Group Study 
E1499. J Clin Oncol 2012;30:3119–3126.\n\n61. Fenske TS, Carreras J, Zhang M, 
et al. Outcome of patients with mantle cell\nlymphoma undergoing autologous 
versus reduced-intensity allogeneic trans-\nplantation. Ann Onc 
2011;22:18a.\n\n62. Tam CS, Bassett R, Ledesma C, et al. Mature results of the 
M. D. Anderson\nCancer Center risk-adapted transplantation strategy in mantle 
cell lymphoma.\n\nBlood 2009;113:4144–4152.\n63. Maris MB, Sandmaier M, Storer 
FE, et al. Allogeneic hematopoietic cell trans-\n\nplantation after fludarabine 
and 2 Gy total body irradiation for relapsed and\nrefractory mantle cell 
lymphoma. Blood 2004;104:3535–3542.\n\nannual clinical updates in hematological 
malignancies: a continuing medical education series\n\n1088 American Journal of 
Hematology\n\n\n\n\n",
+         "X-TIKA:parse_time_millis": "366163",
+         "access_permission:assemble_document": "true",
+         "access_permission:can_modify": "true",
+         "access_permission:can_print": "true",
+         "access_permission:can_print_degraded": "true",
+         "access_permission:extract_content": "true",
+         "access_permission:extract_for_accessibility": "true",
+         "access_permission:fill_in_form": "true",
+         "access_permission:modify_annotations": "true",
+         "created": "Wed Nov 20 05:24:11 PST 2013",
+         "ctakes:AnatomicalSiteMention": [
+             "Cell:189:193:C0007634,C1269647",
+             "Media:432:437:C0162867",
+             "Media:593:598:C0162867",
+             "cell:967:971:C0007634,C1269647",
+             "cell:1045:1049:C0007634,C1269647",
+             "cell:1124:1128:C0007634,C1269647",
+             "Media:2134:2139:C0162867",
+             "cell:3716:3720:C0007634,C1269647",
+             "cell:3839:3843:C0007634,C1269647",
+             "lymph nodes:3920:3931:C1269047,C0024204",
+             "spleen:3933:3939:C1278932,C0037993",
+             "blood:3941:3946:C0005767",
+             "bone marrow:3952:3963:C0005953,C0005953,C0005953",
+             
"bone:3952:3956:C0262950,C1266909,C0391978,C1266908,C0262950,C0391978",
+             "lymph node:4093:4103:C1269047,C0024204",
+             "bone marrow:4105:4116:C0005953,C0005953,C0005953",
+             
"bone:4105:4109:C1266909,C0262950,C0391978,C1266908,C0262950,C0391978",
+             "tissue:4121:4127:C0040300",
+             "cell type:4174:4183:C0007634",
+             "cell:4174:4178:C1269647,C0007634",
+             "cells:4205:4210:C1269647,C0007634",
+             "chromosomal:4214:4225:C0008633",
+             "lymphocytic:4525:4536:C0024264",
+             "Cell:4628:4632:C1269647,C0007634",
+             "leukocyte:4766:4775:C0023516,C0023516",
+             "stem cell:5325:5334:C0038250,C0018956,C0038250",
+             "cell:5330:5334:C0007634,C1269647",
+             "R:5462:5463:C0035639",
+             "R:5470:5471:C0035639",
+             "cells:5596:5601:C0007634,C1269647",
+             "stem cell:5882:5891:C0038250,C0038250,C0018956",
+             "cell:5887:5891:C0007634,C1269647",
+             "cell:6039:6043:C0007634,C1269647",
+             "lymphocytic:6178:6189:C0024264",
+             "cells:6326:6331:C0007634,C1269647",
+             "blood:6868:6873:C0005767",
+             "bone marrow:6878:6889:C0005953,C0005953,C0005953",
+             
"bone:6878:6882:C0262950,C1266909,C1266908,C0391978,C0262950,C0391978",
+             "blood:7153:7158:C0005767",
+             "gastrointestinal tract:7259:7281:C0017189,C0017189,C1281182",
+             "colon:7306:7311:C0009368,C1281569,C0009368",
+             "liver:7313:7318:C0023884,C1278929",
+             "mucosa:7543:7549:C0026724,C0026724,C0026724",
+             "colon:7557:7562:C0009368,C0009368,C1281569",
+             "lacrimal glands:7743:7758:C1278886,C0022907",
+             "glands:7752:7758:C1285092,C1285092,C1285092",
+             "central nervous system:7764:7786:C1269563,C0927232",
+             "nervous system:7772:7786:C0027763,C0027763,C1269560",
+             "lymph node:7840:7850:C1269047,C0024204",
+             "bone marrow:7861:7872:C0005953,C0005953,C0005953",
+             
"bone:7861:7865:C1266908,C0262950,C0391978,C1266909,C0391978,C0262950",
+             "blood:7877:7882:C0005767",
+             "cells:7973:7978:C0007634,C1269647",
+             "cell:8081:8085:C1269647,C0007634",
+             "cells:8209:8214:C1269647,C0007634",
+             "chromosomal:8319:8330:C0008633",
+             "bone marrow:9903:9914:C0005953,C0005953,C0005953",
+             
"bone:9903:9907:C0262950,C0391978,C0262950,C0391978,C1266908,C1266909",
+             "blood:9919:9924:C0005767",
+             "chest:9956:9961:C0817096,C0817096",
+             "abdomen:9963:9970:C1281594,C0000726,C0230168,C0000726",
+             "pelvis:9976:9982:C0030797,C1279864,C0030797,C0559769",
+             "gastrointestinal tract:10194:10216:C0017189,C0017189,C1281182",
+             "cere:10337:10341:C0220805",
+             "B-cell:10668:10674:C0004561",
+             "cell:10670:10674:C0007634,C1269647",
+             "cell:10873:10877:C0007634,C1269647",
+             "white blood cell:11115:11131:C0023516,C0023516",
+             "blood cell:11121:11131:C0005773",
+             "blood:11121:11126:C0005767",
+             "cell:11127:11131:C1269647,C0007634",
+             "less:11608:11612:C0227192",
+             "Blood:12447:12452:C0005767",
+             "scale:12810:12815:C0222045",
+             "tissue:12909:12915:C0040300",
+             "R:15462:15463:C0035639",
+             "R:15509:15510:C0035639",
+             "R:16016:16017:C0035639",
+             "R:16594:16595:C0035639",
+             "R:16662:16663:C0035639",
+             "R:16680:16681:C0035639",
+             
"arm:16805:16808:C1140618,C1140618,C1269078,C1140618,C0446516,C1269612",
+             "R:16847:16848:C0035639",
+             "R:17190:17191:C0035639",
+             "R:17332:17333:C0035639",
+             
"arm:17428:17431:C1269078,C1269612,C1140618,C1140618,C1140618,C0446516",
+             "R:17505:17506:C0035639",
+             
"arm:17520:17523:C1140618,C0446516,C1140618,C1269612,C1140618,C1269078",
+             "R:17568:17569:C0035639",
+             "R:17629:17630:C0035639",
+             "R:17989:17990:C0035639",
+             "R:18023:18024:C0035639",
+             "stem cell:18458:18467:C0038250,C0018956,C0038250",
+             "cell:18463:18467:C0007634,C1269647",
+             
"arm:18561:18564:C1140618,C1269078,C1269612,C1140618,C1140618,C0446516",
+             
"arm:18613:18616:C0446516,C1269612,C1140618,C1140618,C1269078,C1140618",
+             
"arm:18644:18647:C1140618,C1269078,C0446516,C1140618,C1140618,C1269612",
+             "white blood cells:18942:18959:C0023516,C0023516",
+             "blood cells:18948:18959:C0005773",
+             "blood:18948:18953:C0005767",
+             "cells:18954:18959:C0007634,C1269647",
+             "WBC:19039:19042:C0023516,C0023516",
+             "R:19995:19996:C0035639",
+             "R:20250:20251:C0035639",
+             "R:21066:21067:C0035639",
+             "R:21138:21139:C0035639",
+             "stem cell:21200:21209:C0038250,C0018956,C0038250",
+             "cell:21205:21209:C0007634,C1269647",
+             "stem cell:21331:21340:C0038250,C0018956,C0038250",
+             "cell:21336:21340:C0007634,C1269647",
+             "R:21505:21506:C0035639",
+             "R:21520:21521:C0035639",
+             "R:21589:21590:C0035639",
+             "R:21861:21862:C0035639",
+             "R:22008:22009:C0035639",
+             "R:22091:22092:C0035639",
+             "B-cell:24979:24985:C0004561",
+             "cell:24981:24985:C0007634,C1269647",
+             "transplant:25958:25968:C0332835",
+             "transplant:26055:26065:C0332835",
+             "stem cell:26460:26469:C0038250,C0018956,C0038250",
+             "cell:26465:26469:C1269647,C0007634",
+             "stem cell:26740:26749:C0038250,C0018956,C0038250",
+             "cell:26745:26749:C1269647,C0007634",
+             "transplant:26750:26760:C0332835",
+             "graft:26944:26949:C0332835",
+             "stem cell:27408:27417:C0018956,C0038250,C0038250",
+             "cell:27413:27417:C1269647,C0007634",
+             "transplant:27468:27478:C0332835",
+             "R:27723:27724:C0035639",
+             "lymphocytic:28018:28029:C0024264",
+             "Blood:28225:28230:C0005767",
+             "Tumors of theHaematopietic and Lymphoid 
Tissues:28313:28360:C0475358",
+             "Lymphoid Tissues:28344:28360:C0024296,C0024296",
+             "Tissues:28353:28360:C0040300",
+             "Blood:28501:28506:C0005767",
+             "cell:28585:28589:C1269647,C0007634",
+             "cell:28660:28664:C0007634,C1269647",
+             "cell:28862:28866:C1269647,C0007634",
+             "cell:28947:28951:C1269647,C0007634",
+             "Blood:28962:28967:C0005767",
+             "cell:29039:29043:C1269647,C0007634",
+             "cell:29253:29257:C1269647,C0007634",
+             "R:29302:29303:C0035639",
+             "cellular:29320:29328:C0007634",
+             "cell:29346:29350:C0007634,C1269647",
+             "Cell:29376:29380:C0007634,C1269647",
+             "cell:29491:29495:C1269647,C0007634",
+             "cell:29704:29708:C1269647,C0007634",
+             "Cancer Cell:29719:29730:C0334227",
+             "Cell:29726:29730:C1269647,C0007634",
+             "cell:29863:29867:C1269647,C0007634",
+             "R:29930:29931:C0035639",
+             "cell:29977:29981:C0007634,C1269647",
+             "Gill:30227:30231:C0017558",
+             "cell:30407:30411:C0007634,C1269647",
+             "Central nervous system:30501:30523:C0927232,C1269563",
+             "nervous system:30509:30523:C0027763,C1269560,C0027763",
+             "cell:30545:30549:C0007634,C1269647",
+             "cell:30849:30853:C1269647,C0007634",
+             "Blood:30864:30869:C0005767",
+             "cell:30943:30947:C1269647,C0007634",
+             "stem cell:31136:31145:C0018956,C0038250,C0038250",
+             "cell:31141:31145:C0007634,C1269647",
+             "Blood:31170:31175:C0005767",
+             "cell:31365:31369:C1269647,C0007634",
+             "Cancer Cell:31380:31391:C0334227",
+             "Cell:31387:31391:C1269647,C0007634",
+             "cell:31500:31504:C0007634,C1269647",
+             "tissue:31565:31571:C0040300",
+             "cell:31692:31696:C1269647,C0007634",
+             "cell:31792:31796:C0007634,C1269647",
+             "cell:32084:32088:C0007634,C1269647",
+             "cell:32128:32132:C0007634,C1269647",
+             "B-cell:32166:32172:C0004561",
+             "cell:32168:32172:C0007634,C1269647",
+             "lymphocytic:32173:32184:C0024264",
+             "cell:32331:32335:C1269647,C0007634",
+             "cell:32721:32725:C0007634,C1269647",
+             "cell:33067:33071:C0007634,C1269647",
+             "cell:33223:33227:C1269647,C0007634",
+             "cell:33360:33364:C0007634,C1269647",
+             "cell:33559:33563:C1269647,C0007634",
+             "R:33856:33857:C0035639",
+             "R:33936:33937:C0035639",
+             "Blood:34079:34084:C0005767",
+             "B-cell:34210:34216:C0004561",
+             "cell:34212:34216:C0007634,C1269647",
+             "cell:34237:34241:C0007634,C1269647",
+             "stem cell:34396:34405:C0038250,C0018956,C0038250",
+             "cell:34401:34405:C1269647,C0007634",
+             "cell:34499:34503:C0007634,C1269647",
+             "Blood:34587:34592:C0005767",
+             "cell:34743:34747:C0007634,C1269647",
+             "cell:35145:35149:C0007634,C1269647",
+             "stem cell:35287:35296:C0038250,C0038250,C0018956",
+             "cell:35292:35296:C0007634,C1269647",
+             "transplant:35297:35307:C0332835",
+             "cell:35400:35404:C1269647,C0007634",
+             "cell:35533:35537:C0007634,C1269647",
+             "stem cell:35591:35600:C0038250,C0018956,C0038250",
+             "cell:35596:35600:C0007634,C1269647",
+             "cell:35738:35742:C1269647,C0007634",
+             "stem cell:35817:35826:C0018956,C0038250,C0038250",
+             "cell:35822:35826:C0007634,C1269647",
+             "Blood:35907:35912:C0005767",
+             "R:36189:36190:C0035639",
+             "stem cell transplantation in mantle 
cell:36272:36312:C0018956,C0038250,C0038250",
+             "stem cell:36272:36281:C0018956,C0038250,C0038250",
+             "cell:36277:36281:C1269647,C0007634",
+             "cell:36308:36312:C1269647,C0007634",
+             "cell:36534:36538:C1269647,C0007634",
+             "Blood:36588:36593:C0005767",
+             "cell:36754:36758:C1269647,C0007634",
+             "cell:37134:37138:C0007634,C1269647",
+             "cell:37312:37316:C1269647,C0007634",
+             "cell:37455:37459:C1269647,C0007634",
+             "cell:37732:37736:C1269647,C0007634",
+             "Blood:37747:37752:C0005767",
+             "cell:37822:37826:C1269647,C0007634",
+             "Blood:37918:37923:C0005767",
+             "cell:38041:38045:C1269647,C0007634",
+             "R:38162:38163:C0035639",
+             "cell:38321:38325:C1269647,C0007634",
+             "oral:38436:38440:C0226896",
+             "oral:38624:38628:C0226896",
+             "cell:38688:38692:C1269647,C0007634",
+             "Blood:38749:38754:C0005767",
+             "R:38789:38790:C0035639",
+             "cell:38861:38865:C0007634,C1269647",
+             "cell:39132:39136:C1269647,C0007634",
+             "cell:39302:39306:C0007634,C1269647",
+             "cell:39546:39550:C1269647,C0007634",
+             "cell:39711:39715:C0007634,C1269647",
+             "cell:39968:39972:C0007634,C1269647",
+             "R:40265:40266:C0035639",
+             "cell:40384:40388:C0007634,C1269647",
+             "Blood:40398:40403:C0005767",
+             "cell:40493:40497:C0007634,C1269647",
+             "total body:40542:40552:C0229960",
+             "cell:40599:40603:C1269647,C0007634",
+             "Blood:40614:40619:C0005767"
+         ],
+         "ctakes:DateAnnotation": [
+             "October 2013:8713:8725:",
+             "1/2:35241:35244:",
+             "1/2:39154:39157:"
+         ],
+         "ctakes:DiseaseDisorderMention": [
+             "Mantle Cell 
Lymphoma:182:202:C0334634,C0334634,C0334634,C0334634",
+             
"Lymphoma:194:202:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"ards:1673:1677:C0035222,C0035222,C0035222,C0035222,C0035222,C0035222",
+             "dis:1955:1958:C0012634",
+             "HEMATOLOGICAL MALIGNANCIES:3645:3671:C0376545,C0376545,C0376545",
+             
"MALIGNANCIES:3659:3671:C1306459,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826",
+             
"lymphoma:3721:3729:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Disease:3814:3821:C0012634",
+             "Mantle cell 
lymphoma:3832:3852:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:3844:3852:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:3854:3857:C0334634,C0334634,C0334634,C0334634",
+             "non-Hodgkin 
lymphoma:3864:3884:C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305",
+             
"lymphoma:3876:3884:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "chromosomal translocation:4214:4239:C0040715",
+             "translocation:4226:4239:C0040715",
+             "t:4240:4241:C0040715",
+             "MCL:4279:4282:C0334634,C0334634,C0334634,C0334634",
+             "absence:4396:4403:C1689985",
+             "MCL:4472:4475:C0334634,C0334634,C0334634,C0334634",
+             "MCL:4506:4509:C0334634,C0334634,C0334634,C0334634",
+             "small lymphocytic 
lymphoma:4519:4545:C0855095,C0023434,C0855095,C0023434,C0855095,C0023434,C0023434",
+             "lymphocytic 
lymphoma:4525:4545:C0023434,C0855095,C0855095,C0023434,C0023434,C0023434,C0855095",
+             
"lymphoma:4537:4545:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "marginal zone lymphoma:4547:4569:C1367654,C1367654,C1367654",
+             
"lymphoma:4561:4569:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphoma:4587:4595:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Mantle Cell 
Lymphoma:4621:4641:C0334634,C0334634,C0334634,C0334634",
+             
"Lymphoma:4633:4641:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:5135:5138:C0334634,C0334634,C0334634,C0334634",
+             "MCL:5253:5256:C0334634,C0334634,C0334634,C0334634",
+             "MCL:5383:5386:C0334634,C0334634,C0334634,C0334634",
+             "relapse:5542:5549:C0277556",
+             "MCL:5592:5595:C0334634,C0334634,C0334634,C0334634",
+             "MCL:5843:5846:C0334634,C0334634,C0334634,C0334634",
+             "Disease:6016:6023:C0012634",
+             
"lymphoma:6044:6052:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:6054:6057:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:6129:6137:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphoma:6156:6164:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "lymphocytic 
lymphoma:6178:6198:C0855095,C0023434,C0023434,C0855095,C0023434,C0855095,C0023434",
+             
"lymphoma:6190:6198:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:6278:6281:C0334634,C0334634,C0334634,C0334634",
+             "mantle zone 
lymphoma:6397:6417:C0555202,C0334634,C0334634,C0555202,C0334634,C0334634",
+             
"lymphoma:6409:6417:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:6527:6530:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:6550:6558:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphoma:6597:6605:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:6613:6616:C0334634,C0334634,C0334634,C0334634",
+             "MCL:6700:6703:C0334634,C0334634,C0334634,C0334634",
+             "disease:6815:6822:C0012634",
+             "MCL:7026:7029:C0334634,C0334634,C0334634,C0334634",
+             
"leukocytosis:7110:7122:C0023518,C0023518,C0023518,C0023518,C0023518,C0023518,C0023518",
+             "polyps:7389:7395:C0032584,C0032584",
+             "polyposis:7428:7437:C0334108",
+             "MCL:7480:7483:C0334634,C0334634,C0334634,C0334634",
+             "blind:7500:7505:C0456909,C0456909,C0456909",
+             "MCL:7603:7606:C0334634,C0334634,C0334634,C0334634",
+             "MCL:7662:7665:C0334634,C0334634,C0334634,C0334634",
+             "MCL:7710:7713:C0334634,C0334634,C0334634,C0334634",
+             "MCL:8042:8045:C0334634,C0334634,C0334634,C0334634",
+             "MCL:8205:8208:C0334634,C0334634,C0334634,C0334634",
+             "chromosomal translocation:8319:8344:C0040715",
+             "translocation:8331:8344:C0040715",
+             "t:8345:8346:C0040715",
+             "MCL:8373:8376:C0334634,C0334634,C0334634,C0334634",
+             "translocation:9024:9037:C0040715",
+             "MCL:9370:9373:C0334634,C0334634,C0334634,C0334634",
+             "absence:9383:9390:C1689985",
+             "MCL:9428:9431:C0334634,C0334634,C0334634,C0334634",
+             "proliferation:9477:9490:C0334094",
+             "MCL:9574:9577:C0334634,C0334634,C0334634,C0334634",
+             "progression:9659:9670:C0242656",
+             "MCL:9674:9677:C0334634,C0334634,C0334634,C0334634",
+             "MCL:10039:10042:C0334634,C0334634,C0334634,C0334634",
+             "MCL:10127:10130:C0334634,C0334634,C0334634,C0334634",
+             "MCL:10858:10861:C0334634,C0334634,C0334634,C0334634",
+             "MCL:10947:10950:C0334634,C0334634,C0334634,C0334634",
+             "proliferation:11667:11680:C0334094",
+             "pathogenesis:12098:12110:C0699748,C0699748",
+             "progression:12115:12126:C0242656",
+             "MCL:12130:12133:C0334634,C0334634,C0334634,C0334634",
+             
"Cancer:12190:12196:C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826",
+             "MCL:12358:12361:C0334634,C0334634,C0334634,C0334634",
+             "hematological 
malignancies:12481:12507:C0376545,C0376545,C0376545",
+             
"malignancies:12495:12507:C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826",
+             "MCL:12646:12649:C0334634,C0334634,C0334634,C0334634",
+             "proliferation:12709:12722:C0334094",
+             "mens:12922:12926:C0027662,C0027662,C0027662",
+             "MCL:13181:13184:C0334634,C0334634,C0334634,C0334634",
+             "dis:13702:13705:C0012634",
+             "MCL:13856:13859:C0334634,C0334634,C0334634,C0334634",
+             "MCL:14064:14067:C0334634,C0334634,C0334634,C0334634",
+             "MCL:14182:14185:C0334634,C0334634,C0334634,C0334634",
+             "MCL:14265:14268:C0334634,C0334634,C0334634,C0334634",
+             "follicular or other indolent 
lymphomas:14375:14413:C0024301,C0024301,C0024301,C0024301,C0024301,C0024301,C0024301,C0024301,C0024301,C0024301,C0024301,C0024301,C0024301",
+             
"lymphomas:14404:14413:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:15117:15120:C0334634,C0334634,C0334634,C0334634",
+             "MCL:15392:15395:C0334634,C0334634,C0334634,C0334634",
+             "MCL:15484:15487:C0334634,C0334634,C0334634,C0334634",
+             "MCL:15536:15539:C0334634,C0334634,C0334634,C0334634",
+             "progression:15764:15775:C0242656",
+             
"lymphoma:15962:15970:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:16307:16310:C0334634,C0334634,C0334634,C0334634",
+             "MCL:16612:16615:C0334634,C0334634,C0334634,C0334634",
+             "MCL:17038:17041:C0334634,C0334634,C0334634,C0334634",
+             "MCL:17094:17097:C0334634,C0334634,C0334634,C0334634",
+             
"lymphomas:17239:17248:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:17287:17290:C0334634,C0334634,C0334634,C0334634",
+             "progression:17385:17396:C0242656",
+             "toxicity:17467:17475:C0600688,C0600688",
+             "MCL:18191:18194:C0334634,C0334634,C0334634,C0334634",
+             "MCL:18280:18283:C0334634,C0334634,C0334634,C0334634",
+             "hematological 
malignancies:19184:19210:C0376545,C0376545,C0376545",
+             
"malignancies:19198:19210:C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C1306459,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826",
+             "toxicity:19824:19832:C0600688,C0600688",
+             "MCL:20146:20149:C0334634,C0334634,C0334634,C0334634",
+             "MCL:20505:20508:C0334634,C0334634,C0334634,C0334634",
+             "MCL:21450:21453:C0334634,C0334634,C0334634,C0334634",
+             "relapse:22208:22215:C0277556",
+             "relapsed:22248:22256:C0277556",
+             "MCL:22274:22277:C0334634,C0334634,C0334634,C0334634",
+             "MCL:22373:22376:C0334634,C0334634,C0334634,C0334634",
+             "MCL:22565:22568:C0334634,C0334634,C0334634,C0334634",
+             "relapsed:22621:22629:C0277556",
+             "MCL:22641:22644:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:22744:22752:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:22794:22797:C0334634,C0334634,C0334634,C0334634",
+             "MCL:23076:23079:C0334634,C0334634,C0334634,C0334634",
+             "progression:23251:23262:C0242656",
+             "MCL:23470:23473:C0334634,C0334634,C0334634,C0334634",
+             "MCL:23587:23590:C0334634,C0334634,C0334634,C0334634",
+             "relapsed:23704:23712:C0277556",
+             "MCL:23724:23727:C0334634,C0334634,C0334634,C0334634",
+             "tem:23744:23747:C0276640",
+             "relapsed:23841:23849:C0277556",
+             "MCL:23874:23877:C0334634,C0334634,C0334634,C0334634",
+             "MCL:24052:24055:C0334634,C0334634,C0334634,C0334634",
+             "MCL:24142:24145:C0334634,C0334634,C0334634,C0334634",
+             "MCL:24340:24343:C0334634,C0334634,C0334634,C0334634",
+             "relapsed:24457:24465:C0277556",
+             "MCL:24466:24469:C0334634,C0334634,C0334634,C0334634",
+             "MCL:24628:24631:C0334634,C0334634,C0334634,C0334634",
+             "recurrent disease:24680:24697:C0277556",
+             "disease:24690:24697:C0012634",
+             "MCL:24839:24842:C0334634,C0334634,C0334634,C0334634",
+             "MCL:25252:25255:C0334634,C0334634,C0334634,C0334634",
+             "MCL:25395:25398:C0334634,C0334634,C0334634,C0334634",
+             "relapsed:25516:25524:C0277556",
+             "MCL:25525:25528:C0334634,C0334634,C0334634,C0334634",
+             "relapsed:25775:25783:C0277556",
+             "MCL:25784:25787:C0334634,C0334634,C0334634,C0334634",
+             
"prom:25812:25816:C0015944,C0015944,C0015944,C0015944,C0015944,C0015944,C0015944,C0015944",
+             "MCL:25922:25925:C0334634,C0334634,C0334634,C0334634",
+             "relapsed disease:25973:25989:C0277556",
+             "relapsed:25973:25981:C0277556",
+             "disease:25982:25989:C0012634",
+             "MCL:26070:26073:C0334634,C0334634,C0334634,C0334634",
+             "relapsed:26131:26139:C0277556",
+             "MCL:26140:26143:C0334634,C0334634,C0334634,C0334634",
+             "MCL:26349:26352:C0334634,C0334634,C0334634,C0334634",
+             "hematological 
malignancies:26515:26541:C0376545,C0376545,C0376545",
+             
"malignancies:26529:26541:C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826",
+             "MCL:26680:26683:C0334634,C0334634,C0334634,C0334634",
+             "relapse:26876:26883:C0277556",
+             "graft-versus host disease:26944:26969:C0018133,C0018133",
+             "disease:26962:26969:C0012634",
+             
"infectious:26974:26984:C0009450,C0009450,C0009450,C0009450,C0009450,C0009450,C0009450",
+             "complications:26985:26998:C0009566,C0009566",
+             "relapsed:27139:27147:C0277556",
+             "MCL:27148:27151:C0334634,C0334634,C0334634,C0334634",
+             "relapsed:27191:27199:C0277556",
+             "malignant 
lymphomas:27871:27890:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphomas:27881:27890:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Mantle-zone 
lymphoma:27960:27980:C0334634,C0334634,C0555202,C0334634,C0555202,C0334634",
+             
"lymphoma:27972:27980:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "lymphocytic 
lymphoma:28018:28038:C0855095,C0023434,C0023434,C0023434,C0023434,C0855095,C0855095",
+             
"lymphoma:28030:28038:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Cancer:28040:28046:C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826",
+             "ES:28085:28087:C0553580",
+             "lymphoid neoplasms:28150:28168:C0598798",
+             
"neoplasms:28159:28168:C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651",
+             
"Lymphoma:28204:28212:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Tumors:28313:28319:C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651,C0027651",
+             "Non-Hodgkin’s 
Lymphoma:28390:28412:C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305",
+             
"Lymphoma:28404:28412:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Lymphoma:28479:28487:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:28653:28673:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:28665:28673:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:28675:28678:C0334634,C0334634,C0334634,C0334634",
+             "MCL:28726:28729:C0334634,C0334634,C0334634,C0334634",
+             "mantle cell 
lymphoma:28855:28875:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:28867:28875:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Cancer:28877:28883:C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C1306459,C1306459,C0006826",
+             "mantle cell 
lymphoma:28940:28960:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:28952:28960:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Mantle cell 
lymphoma:29032:29052:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:29044:29052:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Leukemia:29091:29099:C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418",
+             "mantle cell 
lymphoma:29246:29266:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:29258:29266:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:29339:29359:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:29351:29359:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphoma:29496:29504:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "proliferation:29584:29597:C0334094",
+             "mantle cell 
lymphoma:29697:29717:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:29709:29717:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Cancer:29719:29725:C0006826,C1306459,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826",
+             "mantle cell 
lymphoma:29856:29876:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:29868:29876:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Cancer:29878:29884:C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826",
+             
"Leukemia:30031:30039:C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418",
+             "pathogenesis:30113:30125:C0699748,C0699748",
+             
"lymphoma:30140:30148:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "disease:30361:30368:C0012634",
+             "mantle cell 
lymphoma:30400:30420:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:30412:30420:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Lymphoma:30427:30435:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Myeloma:30436:30443:C0026764,C0026764,C0026764,C0026764",
+             
"lymphoma:30550:30558:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Non-Hodgkin’s 
Lymphoma:30602:30624:C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305",
+             
"Lymphoma:30616:30624:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphoma:30702:30710:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:30842:30862:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:30854:30862:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:30936:30956:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:30948:30956:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "proliferation:31245:31258:C0334094",
+             "mantle cell 
lymphoma:31358:31378:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:31370:31378:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Cancer:31380:31386:C0006826,C0006826,C1306459,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826",
+             "mantle-cell 
lymphoma:31493:31513:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:31505:31513:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphoma:31697:31705:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Mantle cell 
lymphoma:31785:31805:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:31797:31805:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Lymphoma:31864:31872:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle-cell 
lymphoma:32077:32097:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:32089:32097:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle-cell 
lymphoma:32121:32141:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:32133:32141:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"immunocytoma:32142:32154:C0242647,C0334633,C0242647,C0334633,C0242647",
+             "small B-cell lymphocytic 
lymphoma:32160:32193:C0855095,C0023434,C0855095,C0023434,C0855095,C0023434,C0023434",
+             "B-cell lymphocytic 
lymphoma:32166:32193:C0079731,C0079731,C0079731",
+             "lymphocytic 
lymphoma:32173:32193:C0023434,C0855095,C0855095,C0023434,C0023434,C0855095,C0023434",
+             
"lymphoma:32185:32193:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphoma:32336:32344:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "progression:32396:32407:C0242656",
+             "mantle cell 
lymphoma:32714:32734:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:32726:32734:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Lymphoma:32803:32811:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"macroglobulinemia:33037:33054:C0024419,C0024419,C0024419,C0024419,C0024419,C0024419,C0024419,C0024419",
+             "mantle cell 
lymphoma:33060:33080:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:33072:33080:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "CF:33183:33185:C0010674,C0010674,C0010674,C0010674",
+             "mantle cell 
lymphoma:33216:33236:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:33228:33236:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Lymphoma:33243:33251:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:33353:33373:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:33365:33373:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle-cell 
lymphomas:33552:33573:C0334634,C0334634,C0334634,C0334634",
+             
"lymphomas:33564:33573:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "non-Hodgkin’s 
lymphoma:34002:34024:C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305",
+             
"lymphoma:34016:34024:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"NHL:34026:34029:C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305",
+             "MCL:34055:34058:C0334634,C0334634,C0334634,C0334634",
+             "diffuse large B-cell 
lymphoma:34196:34225:C0079734,C0079734,C0079734,C0079734,C0079734,C0079734,C0079734,C0079744,C0079734,C0079744",
+             "large B-cell 
lymphoma:34204:34225:C0024302,C0024302,C0079744,C0024302,C0079744,C0024302,C0024302,C0024302,C0024302,C0024302,C0024302,C0024302",
+             "B-cell lymphoma:34210:34225:C0079731,C0079731,C0079731",
+             
"lymphoma:34217:34225:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:34230:34250:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:34242:34250:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "progression:34463:34474:C0242656",
+             "MCL:34573:34576:C0334634,C0334634,C0334634,C0334634",
+             "mantle-cell 
lymphoma:34736:34756:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:34748:34756:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"lymphoma:35049:35057:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Mantle cell 
lymphoma:35138:35158:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:35150:35158:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "MCL:35160:35163:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:35405:35413:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle-cell 
lymphoma:35526:35546:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:35538:35546:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "progression:35703:35714:C0242656",
+             
"lymphoma:35743:35751:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Lymphoma:35891:35899:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "progression:36049:36060:C0242656",
+             
"lymphoma:36089:36097:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:36301:36321:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:36313:36321:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:36527:36547:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:36539:36547:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"NHL:36574:36577:C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305",
+             "toxicity:36710:36718:C0600688,C0600688",
+             "non-Hodgkin’s 
lymphoma:36773:36795:C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305,C0024305",
+             
"lymphoma:36787:36795:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "hematological 
malignancies:36853:36879:C0376545,C0376545,C0376545",
+             
"malignancies:36867:36879:C0006826,C0006826,C1306459,C0006826,C0006826,C1306459,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826",
+             "mantle cell 
lymphoma:37127:37147:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:37139:37147:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:37282:37290:C0277556",
+             "mantle cell 
lymphoma:37305:37325:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:37317:37325:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:37426:37434:C0277556",
+             "mantle cell 
lymphoma:37448:37468:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:37460:37468:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:37691:37699:C0277556",
+             
"lymphoma:37737:37745:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "Mantle cell 
lymphoma:37815:37835:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:37827:37835:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:38025:38033:C0277556",
+             "mantle cell 
lymphoma:38034:38054:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:38046:38054:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Cancer:38116:38122:C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826",
+             "mantle cell 
lymphoma:38314:38334:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:38326:38334:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:38470:38478:C0277556",
+             
"lymphoma:38490:38498:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             
"Leukemia:38500:38508:C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418,C0023418",
+             "relapsed:38658:38666:C0277556",
+             
"lymphoma:38866:38874:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:38879:38887:C0277556",
+             "MCL:38950:38953:C0334634,C0334634,C0334634,C0334634",
+             "relapsed:39102:39110:C0277556",
+             "mantle-cell 
lymphoma:39125:39145:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:39137:39145:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:39273:39281:C0277556",
+             "mantle cell 
lymphoma:39295:39315:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:39307:39315:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:39539:39559:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:39551:39559:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:39681:39689:C0277556",
+             "mantle cell 
lymphoma:39704:39724:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:39716:39724:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "mantle cell 
lymphoma:39961:39981:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:39973:39981:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "TS:40072:40074:C0040963,C0040715,C0040963,C0040963",
+             "mantle cell 
lymphoma:40377:40397:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:40389:40397:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "relapsed:40569:40577:C0277556",
+             "mantle cell 
lymphoma:40592:40612:C0334634,C0334634,C0334634,C0334634",
+             
"lymphoma:40604:40612:C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299,C0024299",
+             "hematological 
malignancies:40666:40692:C0376545,C0376545,C0376545",
+             
"malignancies:40680:40692:C1306459,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826,C0006826,C1306459,C0006826,C0006826"
+         ],
+         "ctakes:FractionAnnotation": [
+             ".1088:19:24:",
+             "2013.:8781:8786:",
+             "10.1002:8857:8864:",
+             ".2:11412:11414:",
+             "11.:11849:11852:",
+             "2.:12301:12303:",
+             "1.5:13505:13508:",
+             "16.5:15844:15848:",
+             "18.8:15880:15884:",
+             ".0054:16106:16111:",
+             ".00024:16144:16150:",
+             "0.0032:16689:16695:",
+             "0.0335:18818:18824:",
+             "0.67:19061:19065:",
+             "6.7001:19067:19073:",
+             "0.67:19082:19086:",
+             "1.500:19144:19149:",
+             "15.000:19151:19157:",
+             "0.004:21606:21611:",
+             "6.7:23266:23269:",
+             "23.5:23295:23299:",
+             "4.8:23959:23962:",
+             "7.5:24368:24371:",
+             "408.2:27823:27828:",
+             "45.3:27917:27921:",
+             "1434.4:28060:28066:",
+             "1392.5:28244:28250:",
+             "2008.6:28382:28388:",
+             "3918.7:28520:28526:",
+             "38.8:28764:28768:",
+             "2480.9:28898:28904:",
+             "1476.10:28982:28989:",
+             "336.11:29112:29118:",
+             "591.12:29286:29292:",
+             "1753.13:29399:29406:",
+             "27.14:29531:29536:",
+             "197.15:29742:29748:",
+             "1418.16:29902:29909:",
+             "1791.17:30053:30060:",
+             "762.18:30219:30225:",
+             "165.19:30455:30461:",
+             "141.20:30580:30586:",
+             "994.21:30738:30744:",
+             "565.22:30883:30889:",
+             "1533.23:31190:31197:",
+             "197.24:31403:31409:",
+             "4972.25:31597:31604:",
+             "1213.26:31731:31738:",
+             "196.27:31910:31916:",
+             "324.28:32218:32224:",
+             "1294.29:32447:32454:",
+             "1992.30:32855:32862:",
+             "553.31:33106:33112:",
+             "1022.32:33265:33272:",
+             "531.33:33393:33399:",
+             "1210.34:33665:33672:",
+             ".35:34098:34101:",
+             "697.36:34274:34280:",
+             "2684.37:34607:34614:",
+             "7023.38:34884:34891:",
+             "1593.39:35091:35098:",
+             "1/2:35241:35244:",
+             ".40:35350:35353:",
+             "3029.41:35644:35651:",
+             "2693.42:35927:35934:",
+             "1423.43:36172:36179:",
+             "53.44:36406:36411:",
+             "2099.45:36607:36614:",
+             "684.47:37174:37180:",
+             "4874.48:37352:37359:",
+             "525.49:37565:37571:",
+             "2812.50:37767:37774:",
+             "38.51:37936:37941:",
+             "514.52:38136:38142:",
+             "3829.53:38362:38369:",
+             "347.54:38521:38527:",
+             "267.55:38768:38774:",
+             "2835.56:38992:38999:",
+             "1/2:39154:39157:",
+             "723.57:39199:39205:",
+             "516.58:39335:39341:",
+             ".59:39581:39584:",
+             "5218.60:39751:39758:",
+             "3126.61:40056:40063:",
+             ".62:40244:40247:",
+             "4152.63:40418:40425:"
+         ],
+         "ctakes:MeasurementAnnotation": [
+             "106 L:18964:18969:",
+             "175 mg:23907:23913:"
+         ],
+         "ctakes:MedicationMention": [
+             "duration:3987:3995:C2926735",
+             "Bendamustine:5472:5484:C0525079,C0525079",
+             "bortezomib:5609:5619:C1176309,C1176309",
+             "Tyrosine:5735:5743:C0041485,C0041485",
+             "formalin:12875:12883:C0949307,C0949307",
+             "paraffin:12891:12899:C0030415",
+             "duration:13466:13474:C2926735",
+             "doxorubicin:14881:14892:C0013089,C0013089",
+             "oncovin:14894:14901:C0591904,C0591904",
+             "prednisone:14907:14917:C0032952,C0032952",
+             "rituximab:14976:14985:C0393022",
+             "rituximab:15416:15425:C0393022",
+             "cyclophosphamide:16425:16441:C0010583,C0010583",
+             "rituximab:16446:16455:C0393022",
+             "rituximab:16777:16786:C0393022",
+             "rituximab:16866:16875:C0393022",
+             "rituximab:16990:16999:C0393022",
+             "Bendamustine:17201:17213:C0525079,C0525079",
+             "Bendamustine:17507:17519:C0525079,C0525079",
+             "Bendamustine:17570:17582:C0525079,C0525079",
+             "rituximab:17999:18008:C0393022",
+             "Bendamustine:18025:18037:C0525079,C0525079",
+             "cytarabine:18753:18763:C0010711",
+             "cyclophosphamide:19300:19316:C0010583,C0010583",
+             "vincristine:19318:19329:C0042679,C0042679",
+             "doxorubicin:19331:19342:C0013089,C0013089",
+             "dexamethasone:19347:19360:C0011777,C0011777",
+             "methotrexate:19402:19414:C0025677,C0025677",
+             "rituximab:19490:19499:C0393022",
+             "cytarabine:19553:19563:C0010711",
+             "cytarabine:20293:20303:C0010711",
+             "methotrexate:20360:20372:C0025677,C0025677",
+             "cytarabine:20421:20431:C0010711",
+             "cytarabine:20728:20738:C0010711",
+             "methotrexate:20897:20909:C0025677,C0025677",
+             "rituximab:20945:20954:C0393022",
+             "Rituximab:21090:21099:C0393022",
+             "cisplatin:21101:21110:C0008838,C0008838",
+             "cytarabine:21112:21122:C0010711",
+             "dexamethasone:21123:21136:C0011777,C0011777",
+             "cytarabine:22035:22045:C0010711",
+             "Bendamustine:22102:22114:C0525079,C0525079",
+             "rituximab:22510:22519:C0393022",
+             "bortezomib:22946:22956:C1176309,C1176309",
+             "bortezomib:22976:22986:C1176309,C1176309",
+             "rituximab:23390:23399:C0393022",
+             "temsirolimus:23644:23656:C1707080,C1707080",
+             "sirolimus:23748:23757:C0072980,C0072980",
+             "doses:23884:23889:C0719635,C0719635",
+             "temsirolimus:23893:23905:C1707080,C1707080",
+             "everolimus:24006:24016:C0541315,C0541315",
+             "lenalidomide:24088:24100:C1144149,C1144149",
+             "lenalidomide:24241:24253:C1144149,C1144149",
+             "lenalidomide:24298:24310:C1144149,C1144149",
+             "bortezomib:24485:24495:C1176309,C1176309",
+             "Lenalidomide:24496:24508:C1144149,C1144149",
+             "rituximab:24537:24546:C0393022",
+             "rituximab:24666:24675:C0393022",
+             "tyrosine:24862:24870:C0041485,C0041485",
+             "bortezomib:25132:25142:C1176309,C1176309",
+             "bortezomib:25195:25205:C1176309,C1176309",
+             "bendamustine:27220:27232:C0525079,C0525079",
+             "rituximab:27233:27242:C0393022",
+             "bendamustine:27285:27297:C0525079,C0525079",
+             "bortezomib:27328:27338:C1176309,C1176309",
+             "formalin:31530:31538:C0949307,C0949307",
+             "paraffin:31546:31554:C0030415",
+             "Rituximab:32268:32277:C0393022",
+             "rituximab:32517:32526:C0393022",
+             "doxorubicin:32548:32559:C0013089,C0013089",
+             "vincristine:32561:32572:C0042679,C0042679",
+             "prednisone:32578:32588:C0032952,C0032952",
+             "fludara:32937:32944:C0700805",
+             "fludarabine:33170:33181:C0059985",
+             "Bendamustine:33444:33456:C0525079,C0525079",
+             "rituximab:33488:33497:C0393022",
+             "level:33725:33730:C2946261",
+             "rituximab:33768:33777:C0393022",
+             "rituximab:33797:33806:C0393022",
+             "vincristine:33827:33838:C0042679,C0042679",
+             "prednisone:33844:33854:C0032952,C0032952",
+             "rituximab:33866:33875:C0393022",
+             "cyclophosphamide:33877:33893:C0010583,C0010583",
+             "doxorubicin:33894:33905:C0013089,C0013089",
+             "vincristine:33907:33918:C0042679,C0042679",
+             "prednisone:33924:33934:C0032952,C0032952",
+             "Bortezomib:34139:34149:C1176309,C1176309",
+             "Rituximab:34160:34169:C0393022",
+             "Rituximab:34805:34814:C0393022",
+             "cytarabine:34848:34858:C0010711",
+             "rituximab:34990:34999:C0393022",
+             "methotrexate:35208:35220:C0025677,C0025677",
+             "cytarabine:35225:35235:C0010711",
+             "purged:35810:35816:C0722910",
+             "rituximab:35987:35996:C0393022",
+             "rituximab:36238:36247:C0393022",
+             "Bendamustine:36645:36657:C0525079,C0525079",
+             "rituximab:36662:36671:C0393022",
+             "bortezomib:37064:37074:C1176309,C1176309",
+             "Bortezomib:37398:37408:C1176309,C1176309",
+             "bendamustine:37632:37644:C0525079,C0525079",
+             "rituximab:37663:37672:C0393022",
+             "basis:37879:37884:C1874451",
+             "lenalidomide:38825:38837:C1144149,C1144149",
+             "bortezomib:38929:38939:C1176309,C1176309",
+             "rituximab:39816:39825:C0393022",
+             "doxorubicin:39850:39861:C0013089,C0013089",
+             "vincristine:39863:39874:C0042679,C0042679",
+             "prednisone:39880:39890:C0032952,C0032952",
+             "fludarabine:40521:40532:C0059985"
+         ],
+         "ctakes:ProcedureMention": [
+             "therapy:1025:1032:C0087111,C0087111,C0087111,C0087111",
+             
"treatment:1095:1104:C0087111,C0087111,C1533734,C0087111,C1533734,C0087111",
+             
"support:1171:1178:C0344211,C0344211,C0344211,C0344211,C0344211,C0344211,C0344211",
+             
"support:1316:1323:C0344211,C0344211,C0344211,C0344211,C0344211,C0344211,C0344211",
+             
"US:1511:1513:C0041618,C0041618,C0041618,C0041618,C0041618,C0041618,C0041618",
+             
"US:1525:1527:C0041618,C0041618,C0041618,C0041618,C0041618,C0041618,C0041618",
+             
"Hematology:1757:1767:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             
"Hematology:1877:1887:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             
"test:2914:2918:C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885",
+             
"Hematology:3554:3564:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             "differential diagnosis:4480:4502:C0011906",
+             "ECOG:4736:4740:C0430797",
+             "leukocyte count:4766:4781:C0023508,C0023508,C0023508,C0023508",
+             "Therapy:5094:5101:C0087111,C0087111,C0087111,C0087111",
+             "observation:5157:5168:C0557985,C0557985",
+             "therapy:5269:5276:C0087111,C0087111,C0087111,C0087111",
+             "autologous stem cell transplantation:5314:5350:C0040736",
+             "transplantation:5335:5350:C0040732,C0040732,C0040732,C0040732",
+             
"chemotherapy:5444:5456:C0013216,C0392920,C0392920,C0013216,C0392920,C0013216,C0392920,C0392920,C0013216,C0013216,C0013216,C0392920",
+             "transplantation:5892:5907:C0040732,C0040732,C0040732,C0040732",
+             
"US:6660:6662:C0041618,C0041618,C0041618,C0041618,C0041618,C0041618,C0041618",
+             "flow cytometry:7203:7217:C0016263",
+             "biopsies:7506:7514:C0005558,C0005558",
+             "biopsy of a lymph node:7828:7850:C0193842",
+             "biopsy:7828:7834:C0005558,C0005558",
+             "phenotype:7883:7892:C1285572",
+             "Immunophenotyping:8162:8179:C0079611",
+             
"Hematology:8419:8429:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             "Division:8568:8576:C1293097,C1293097,C1293097,C1293097",
+             
"Hematology:8580:8590:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             
"Hematology:8925:8935:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             "expression:9060:9070:C0185117,C0185117",
+             "lym:9127:9130:C0200635,C0200635,C0200635,C0200635,C0200635",
+             "procedures:9733:9743:C0184661,C0184661",
+             "LDH:9825:9828:C0202113",
+             "immunophenotyping:9861:9878:C0079611",
+             "PET scanning:10022:10034:C0032743,C0032743,C0032743",
+             "PET:10022:10025:C0032743,C0032743,C0032743",
+             
"scanning:10026:10034:C0034606,C0034606,C0034606,C0034606,C0034606,C0034606,C0441633,C0034606,C0034606,C0034606,C0034606",
+             "Evaluation of the gastrointestinal tract:10176:10216:C2732712",
+             "lym:10687:10690:C0200635,C0200635,C0200635,C0200635,C0200635",
+             "ECOG:11066:11070:C0430797",
+             "LDH:11097:11100:C0202113",
+             "white blood cell 
count:11115:11137:C0023508,C0023508,C0023508,C0023508",
+             "blood cell 
count:11121:11137:C0009555,C0009555,C0009555,C0005771,C0009555",
+             "cell count:11127:11137:C0007584,C0007584,C0007584,C0007584",
+             "Nat:12182:12185:C0200932",
+             "expression:12586:12596:C0185117,C0185117",
+             
"testing:12836:12843:C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885,C0022885",
+             "polymerase chain reaction:13092:13117:C0032520",
+             "PCR:13123:13126:C0032520",
+             "therapies:13351:13360:C0087111,C0087111,C0087111,C0087111",
+             "chemotherapy 
regimens:13432:13453:C0392920,C0392920,C0392920,C0392920,C0392920,C0392920",
+             
"chemotherapy:13432:13444:C0013216,C0392920,C0013216,C0013216,C0392920,C0392920,C0392920,C0013216,C0392920,C0392920,C0013216,C0013216",
+             
"chemotherapy:13562:13574:C0013216,C0013216,C0392920,C0013216,C0013216,C0392920,C0392920,C0392920,C0392920,C0013216,C0013216,C0392920",
+             "therapy:14136:14143:C0087111,C0087111,C0087111,C0087111",
+             
"treatment:14677:14686:C1533734,C0087111,C0087111,C1533734,C0087111,C0087111",
+             
"treatment:14706:14715:C1533734,C0087111,C0087111,C1533734,C0087111,C0087111",
+             "observation:14724:14735:C0557985,C0557985",
+             
"treatment:14831:14840:C1533734,C0087111,C0087111,C1533734,C0087111,C0087111",
+             
"treatment:14929:14938:C1533734,C0087111,C0087111,C1533734,C0087111,C0087111",
+             "therapy:15074:15081:C0087111,C0087111,C0087111,C0087111",
+             "therapy:15176:15183:C0087111,C0087111,C0087111,C0087111",
+             
"treatment:15222:15231:C0087111,C1533734,C0087111,C1533734,C0087111,C0087111",
+             "therapy:15316:15323:C0087111,C0087111,C0087111,C0087111",
+             
"treatment:15523:15532:C0087111,C0087111,C1533734,C0087111,C0087111,C1533734",
+             "therapy:17909:17916:C0087111,C0087111,C0087111,C0087111",
+             
"chemotherapy:18421:18433:C0013216,C0392920,C0013216,C0013216,C0392920,C0392920,C0392920,C0013216,C0013216,C0013216,C0392920,C0392920",
+             "autologous stem cell transplantation:18447:18483:C0040736",
+             "transplantation:18468:18483:C0040732,C0040732,C0040732,C0040732",
+             "ECOG:18869:18873:C0430797",
+             "LDH:18912:18915:C0202113",
+             "LDH:18920:18923:C0202113",
+             "white blood 
cells:18942:18959:C0023508,C0023508,C0023508,C0023508",
+             "ECOG:19019:19023:C0430797",
+             "LDH:19027:19030:C0202113",
+             "LDH:19035:19038:C0202113",
+             "WBC:19039:19042:C0023508,C0023508,C0023508,C0023508",
+             
"Hematology:19269:19279:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             "analysis:20114:20122:C0002778",
+             
"chemotherapy:20618:20630:C0013216,C0013216,C0392920,C0013216,C0013216,C0392920,C0392920,C0392920,C0013216,C0392920,C0013216,C0392920",
+             "autologous stem cell transplantation:21189:21225:C0040736",
+             "transplantation:21210:21225:C0040732,C0040732,C0040732,C0040732",
+             "autologous stem cell transplantation:21320:21356:C0040736",
+             "transplantation:21341:21356:C0040732,C0040732,C0040732,C0040732",
+             "analysis:21434:21442:C0002778",
+             "salvage:22753:22760:C0442967",
+             
"treatment:22805:22814:C0087111,C1533734,C0087111,C0087111,C0087111,C1533734",
+             "mg:23911:23913:C0373675",
+             
"irradiation:25380:25391:C1522449,C1522449,C1522449,C1522449,C1522449",
+             "radioimmunotherapy:25438:25456:C0085101",
+             
"chemotherapy:25736:25748:C0392920,C0392920,C0013216,C0013216,C0392920,C0013216,C0013216,C0392920,C0013216,C0392920,C0392920,C0013216",
+             "transplant:25958:25968:C0040732,C0040732,C0040732,C0040732",
+             "transplant:26055:26065:C0040732,C0040732,C0040732,C0040732",
+             
"Hematology:26605:26615:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             "transplant:26750:26760:C0040732,C0040732,C0040732,C0040732",
+             "allogeneic transplantation:26903:26929:C0040739",
+             "transplantation:26914:26929:C0040732,C0040732,C0040732,C0040732",
+             "autologous stemcell transplantation:27099:27134:C0040736",
+             "transplantation:27119:27134:C0040732,C0040732,C0040732,C0040732",
+             "transplantation:27418:27433:C0040732,C0040732,C0040732,C0040732",
+             "transplant:27468:27478:C0040732,C0040732,C0040732,C0040732",
+             "therapy:27678:27685:C0087111,C0087111,C0087111,C0087111",
+             "K:27744:27745:C0202194",
+             "RF:27849:27851:C0201660,C0201660,C0201660",
+             "lym:29982:29985:C0200635,C0200635,C0200635,C0200635,C0200635",
+             "Nat:30194:30197:C0200932",
+             
"scanning:30314:30322:C0034606,C0034606,C0034606,C0034606,C0034606,C0034606,C0034606,C0034606,C0034606,C0034606,C0441633",
+             "transplantation:31146:31161:C0040732,C0040732,C0040732,C0040732",
+             "therapy:31675:31682:C0087111,C0087111,C0087111,C0087111",
+             
"treatment:32632:32641:C1533734,C0087111,C0087111,C1533734,C0087111,C0087111",
+             "phosphate:32950:32959:C0523826",
+             "lym:33012:33015:C0200635,C0200635,C0200635,C0200635,C0200635",
+             
"treatment:33203:33212:C0087111,C0087111,C0087111,C1533734,C1533734,C0087111",
+             
"Treatment:33321:33330:C1533734,C0087111,C0087111,C1533734,C0087111,C0087111",
+             
"treatment:33512:33521:C0087111,C1533734,C0087111,C0087111,C1533734,C0087111",
+             
"treatment:33958:33967:C0087111,C0087111,C1533734,C0087111,C0087111,C1533734",
+             "autologous stem cell transplantation:34385:34421:C0040736",
+             "transplantation:34406:34421:C0040732,C0040732,C0040732,C0040732",
+             "lym:34504:34507:C0200635,C0200635,C0200635,C0200635,C0200635",
+             
"treatment:34696:34705:C1533734,C0087111,C0087111,C0087111,C0087111,C1533734",
+             "transplant:35297:35307:C0040732,C0040732,C0040732,C0040732",
+             "therapy:35567:35574:C0087111,C0087111,C0087111,C0087111",
+             "transplantation:35601:35616:C0040732,C0040732,C0040732,C0040732",
+             "autologous stem cell transplantation:36261:36297:C0040736",
+             "transplantation:36282:36297:C0040732,C0040732,C0040732,C0040732",
+             "therapy:36493:36500:C0087111,C0087111,C0087111,C0087111",
+             "analysis:36552:36560:C0002778",
+             
"treatment:36734:36743:C1533734,C0087111,C0087111,C0087111,C1533734,C0087111",
+             
"Hematology:36938:36948:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627",
+             
"treatment:37888:37897:C1533734,C0087111,C1533734,C0087111,C0087111,C0087111",
+             
"Treatment:38099:38108:C1533734,C0087111,C1533734,C0087111,C0087111,C0087111",
+             
"treatment:38279:38288:C0087111,C0087111,C0087111,C1533734,C0087111,C1533734",
+             "lym:38693:38696:C0200635,C0200635,C0200635,C0200635,C0200635",
+             "transplantation:40349:40364:C0040732,C0040732,C0040732,C0040732",
+             "FE:40457:40459:C0337439",
+             "total body irradiation:40542:40564:C0043162",
+             
"irradiation:40553:40564:C1522449,C1522449,C1522449,C1522449,C1522449",
+             
"Hematology:40756:40766:C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627,C0200627"
+         ],
+         "ctakes:RomanNumeralAnnotation": [
+             "M:127:128:",
+             "M:161:162:",
+             "D:163:164:",
+             "VC:3503:3505:",
+             "MCL:3854:3857:",
+             "MCL:4279:4282:",
+             "MCL:4472:4475:",
+             "MCL:4506:4509:",
+             "MCL:5135:5138:",
+             "MCL:5253:5256:",
+             "MCL:5383:5386:",
+             "MCL:5592:5595:",
+             "MCL:5843:5846:",
+             "VC:5985:5987:",
+             "MCL:6054:6057:",
+             "MCL:6278:6281:",
+             "MCL:6527:6530:",
+             "MCL:6613:6616:",
+             "MCL:6700:6703:",
+             "III:6808:6811:",
+             "IV:6812:6814:",
+             "MCL:7026:7029:",
+             "MCL:7480:7483:",
+             "MCL:7603:7606:",
+             "MCL:7662:7665:",
+             "MCL:7710:7713:",
+             "MCL:8042:8045:",
+             "MCL:8205:8208:",
+             "MCL:8373:8376:",
+             "MCL:9370:9373:",
+             "MCL:9428:9431:",
+             "MCL:9574:9577:",
+             "MCL:9674:9677:",
+             "MCL:10039:10042:",
+             "MCL:10127:10130:",
+             "III:10502:10505:",
+             "IV:10509:10511:",
+             "MLC:10735:10738:",
+             "MCL:10858:10861:",
+             "MCL:10947:10950:",
+             "I:11482:11483:",
+             "II:11749:11751:",
+             "MCL:12130:12133:",
+             "MCL:12358:12361:",
+             "MCL:12646:12649:",
+             "MCL:13181:13184:",
+             "MCL:13856:13859:",
+             "II:13974:13976:",
+             "MCL:14064:14067:",
+             "MCL:14182:14185:",
+             "MCL:14265:14268:",
+             "MCL:15117:15120:",
+             "MCL:15392:15395:",
+             "MCL:15484:15487:",
+             "MCL:15536:15539:",
+             "did:15871:15874:",
+             "did:16171:16174:",
+             "MCL:16307:16310:",
+             "MCL:16612:16615:",
+             "MCL:17038:17041:",
+             "MCL:17094:17097:",
+             "MCL:17287:17290:",
+             "did:17583:17586:",
+             "did:17647:17650:",
+             "MCL:18191:18194:",
+             "MCL:18280:18283:",
+             "L:18968:18969:",
+             "II:18976:18978:",
+             "IV:19809:19811:",
+             "MCL:20146:20149:",
+             "MCL:20505:20508:",
+             "X:21073:21074:",
+             "X:21146:21147:",
+             "MCL:21450:21453:",
+             "MCL:22274:22277:",
+             "MCL:22373:22376:",
+             "MCL:22565:22568:",
+             "II:22587:22589:",
+             "MCL:22641:22644:",
+             "MCL:22794:22797:",
+             "II:23050:23052:",
+             "MCL:23076:23079:",
+             "II:23197:23199:",
+             "MCL:23470:23473:",
+             "MCL:23587:23590:",
+             "II:23679:23681:",
+             "MCL:23724:23727:",
+             "III:23824:23827:",
+             "MCL:23874:23877:",
+             "MCL:24052:24055:",
+             "MCL:24142:24145:",
+             "II:24158:24160:",
+             "MCL:24340:24343:",
+             "MCL:24466:24469:",
+             "MCL:24628:24631:",
+             "MCL:24839:24842:",
+             "MCL:25252:25255:",
+             "MCL:25395:25398:",
+             "MCL:25525:25528:",
+             "MCL:25784:25787:",
+             "MCL:25922:25925:",
+             "MCL:26070:26073:",
+             "MCL:26140:26143:",
+             "MCL:26349:26352:",
+             "MCL:26680:26683:",
+             "MCL:27148:27151:",
+             "I:27733:27734:",
+             "DD:27936:27938:",
+             "M:28536:28537:",
+             "C:28548:28549:",
+             "MCL:28675:28678:",
+             "MCL:28726:28729:",
+             "I:28791:28792:",
+             "M:28916:28917:",
+             "I:28932:28933:",
+             "C:29010:29011:",
+             "V:29760:29761:",
+             "M:29919:29920:",
+             "D:30079:30080:",
+             "M:30240:30241:",
+             "M:30765:30766:",
+             "V:31433:31434:",
+             "V:31443:31444:",
+             "DD:31753:31755:",
+             "D:31953:31954:",
+             "II:31978:31980:",
+             "M:32473:32474:",
+             "II:32925:32927:",
+             "C:33134:33135:",
+             "D:33144:33145:",
+             "M:33408:33409:",
+             "MCL:34055:34058:",
+             "M:34291:34292:",
+             "MCL:34573:34576:",
+             "L:34636:34637:",
+             "II:34941:34943:",
+             "C:34984:34985:",
+             "MCL:35160:35163:",
+             "MC:35237:35239:",
+             "C:36199:36200:",
+             "V:36209:36210:",
+             "d:36354:36355:",
+             "l:36379:36380:",
+             "M:36623:36624:",
+             "C:36990:36991:",
+             "II:37006:37008:",
+             "II:37241:37243:",
+             "M:37800:37801:",
+             "III:38191:38194:",
+             "II:38420:38422:",
+             "II MCL:38947:38953:",
+             "II:38947:38949:",
+             "M:39006:39007:",
+             "L:39015:39016:",
+             "L:39212:39213:",
+             "I:39365:39366:",
+             "M:39591:39592:",
+             "II:39621:39623:",
+             "LI:39787:39789:",
+             "II:39804:39806:",
+             "M:40094:40095:",
+             "C:40276:40277:",
+             "M:40447:40448:"
+         ],
+         "ctakes:SignSymptomMention": [
+             
"education:43:52:C0013658,C0013658,C0013658,C0424927,C0013658,C0013658,C0013658,C0013658",
+             "M:127:128:C0024554,C0024554,C0024554,C0024554",
+             "M:161:162:C0024554,C0024554,C0024554,C0024554",
+             "Services:438:446:C0557854",
+             
"Education:512:521:C0013658,C0013658,C0013658,C0013658,C0013658,C0424927,C0013658,C0013658",
+             
"education:551:560:C0013658,C0013658,C0013658,C0013658,C0013658,C0424927,C0013658,C0013658",
+             "Services:599:607:C0557854",
+             "interest:1808:1816:C0543488",
+             "identities:1919:1929:C0424215",
+             "dis:1955:1958:C1444662",
+             "interest:2056:2064:C0543488",
+             "Services:2140:2148:C0557854",
+             "Interest:2196:2204:C0543488",
+             "contents:3088:3096:C0423896",
+             "contents:3149:3157:C0423896",
+             
"VC:3503:3505:C0042834,C0042834,C0042834,C0042834,C0042834,C0042834",
+             
"EDUCATION:3693:3702:C0013658,C0013658,C0013658,C0013658,C0424927,C0013658,C0013658,C0013658",
+             "diagnosis:3746:3755:C0011900",
+             "remission:3977:3986:C0544452,C0544452,C0544452",
+             "Diagnosis:4060:4069:C0011900",
+             "Diagnosis:4071:4080:C0011900",
+             "diagnosis:4493:4502:C0011900",
+             "OS:4921:4923:C0232275",
+             "OS:4972:4974:C0232275",
+             "OS:4995:4997:C0232275",
+             
"VC:5985:5987:C0042834,C0042834,C0042834,C0042834,C0042834,C0042834",
+             "male:6754:6758:C0024554,C0024554,C0024554,C0024554",
+             
"adenopathy:6856:6866:C0497156,C0497156,C0497156,C0497156,C0497156,C0497156,C0497156,C0497156,C0497156,C0497156,C0497156,C0497156,C0497156,C0497156",
+             
"splenomegaly:6988:7000:C0038002,C0038002,C0038002,C0038002,C0038002,C0038002,C0038002",
+             "diagnosis:7467:7476:C0011900",
+             "normal:7526:7532:C0558145",
+             "nervous:7772:7779:C0027769,C0027769,C0027769,C0027769,C0027769",
+             "diagnosis:7805:7814:C0011900",
+             "tis:7852:7855:C0475413,C0475413",
+             "interest:8505:8513:C0543488",
+             "Nothing:8515:8522:C0442735",
+             "expression:9060:9070:C0017262",
+             "normal:9120:9126:C0558145",
+             "proliferation index:9477:9496:C0812425",
+             "mutations:9504:9513:C0026882",
+             
"symptoms:10268:10276:C1457887,C1457887,C1457887,C1457887,C1457887,C1457887",
+             
"symptoms:10409:10417:C1457887,C1457887,C1457887,C1457887,C1457887,C1457887",
+             "worse:11060:11065:C1279889",
+             "OS:11290:11292:C0232275",
+             "OS:11335:11337:C0232275",
+             "OS:11392:11394:C0232275",
+             "proliferation index:11667:11686:C0812425",
+             "issue:12241:12246:C0033213",
+             
"education:12530:12539:C0013658,C0013658,C0013658,C0013658,C0424927,C0013658,C0013658,C0013658",
+             "expression:12586:12596:C0017262",
+             "PCR:13123:13126:C0677874",
+             "context:13281:13288:C0449255",
+             "remissions:13389:13399:C0544452,C0544452,C0544452",
+             "dis:13702:13705:C1444662",
+             
"management:14018:14028:C1273870,C0001554,C0001554,C1273870,C1273870,C0001554,C0001554,C1273870",
+             "asymptomatic:14032:14044:C0231221",
+             "asymptomatic:14232:14244:C0231221",
+             
"elderly:14257:14264:C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792",
+             "asymptomatic:15096:15108:C0231221",
+             
"elderly:15109:15116:C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792",
+             "complete response:15641:15658:C0677874",
+             "CR:15660:15662:C0677874",
+             "CR:15723:15725:C0677874",
+             "CR:15841:15843:C0677874",
+             "P50:16103:16106:C0429403",
+             "CR:16120:16122:C0677874",
+             "P50:16141:16144:C0429403",
+             "OS:16228:16230:C0232275",
+             "OS:16648:16650:C0232275",
+             "OS:16840:16842:C0232275",
+             "OS:16901:16903:C0232275",
+             "Asymptomatic:17839:17851:C0231221",
+             
"elderly:17852:17859:C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792,C0001792",
+             
"management:18067:18077:C1273870,C1273870,C0001554,C1273870,C0001554,C0001554,C0001554,C1273870",
+             "L0:19048:19050:C0441917",
+             
"education:19233:19242:C0013658,C0013658,C0013658,C0013658,C0013658,C0013658,C0013658,C0424927",
+             "CR:19590:19592:C0677874",
+             "OS:19661:19663:C0232275",
+             "CR:19769:19771:C0677874",
+             "ate:20289:20292:C0013470,C0013470",
+             "OS:20672:20674:C0232275",
+             
"Management:22194:22204:C0001554,C0001554,C0001554,C1273870,C1273870,C1273870,C0001554,C1273870",
+             "asymptomatic:22261:22273:C0231221",
+             "CR:22678:22680:C0677874",
+             "signaling:22850:22859:C0037083",
+             "CR:23144:23146:C0677874",
+             "follow up:23176:23185:C0589120,C0589120,C0589120,C0589120",
+             "OS:23289:23291:C0232275",
+             "CR:24373:24375:C0677874",
+             "CR:24737:24739:C0677874",
+             "CR:25089:25091:C0677874",
+             "prom:25812:25816:C0079991",
+             "OS:26001:26003:C0232275",
+             "OS:26086:26088:C0232275",
+             "remission:26166:26175:C0544452,C0544452,C0544452",
+             "source:26450:26456:C0449416",
+             
"education:26564:26573:C0013658,C0013658,C0013658,C0424927,C0013658,C0013658,C0013658,C0013658",
+             "OS:26846:26848:C0232275",
+             "remission:27504:27513:C0544452,C0544452,C0544452",
+             "M:28536:28537:C0024554,C0024554,C0024554,C0024554",
+             "F:28800:28801:C0015780,C0015780,C0015780,C0015780",
+             "M:28916:28917:C0024554,C0024554,C0024554,C0024554",
+             "F:29416:29417:C0015780,C0015780,C0015780,C0015780",
+             "M:29919:29920:C0024554,C0024554,C0024554,C0024554",
+             "F:29941:29942:C0015780,C0015780,C0015780,C0015780",
+             "M:30240:30241:C0024554,C0024554,C0024554,C0024554",
+             "F:30479:30480:C0015780,C0015780,C0015780,C0015780",
+             
"nervous:30509:30516:C0027769,C0027769,C0027769,C0027769,C0027769",
+             "M:30765:30766:C0024554,C0024554,C0024554,C0024554",
+             "diag:32066:32070:C0011900",
+             "M:32473:32474:C0024554,C0024554,C0024554,C0024554",
+             "M:33408:33409:C0024554,C0024554,C0024554,C0024554",
+             "Bright:34065:34071:C0423899,C0423899,C0423899,C0423899,C0423899",
+             "M:34291:34292:C0024554,C0024554,C0024554,C0024554",
+             "work:34581:34585:C0043227",
+             "ate:34840:34843:C0013470,C0013470",
+             "F:35117:35118:C0015780,C0015780,C0015780,C0015780",
+             "remission:35317:35326:C0544452,C0544452,C0544452",
+             "M:36623:36624:C0024554,C0024554,C0024554,C0024554",
+             
"education:36902:36911:C0013658,C0424927,C0013658,C0013658,C0013658,C0013658,C0013658,C0013658",
+             "M:37800:37801:C0024554,C0024554,C0024554,C0024554",
+             "M:39006:39007:C0024554,C0024554,C0024554,C0024554",
+             "M:39591:39592:C0024554,C0024554,C0024554,C0024554",
+             "M:40094:40095:C0024554,C0024554,C0024554,C0024554",
+             "M:40447:40448:C0024554,C0024554,C0024554,C0024554",
+             
"education:40715:40724:C0013658,C0013658,C0013658,C0013658,C0013658,C0424927,C0013658,C0013658"
+         ],
+         "ctakes:schema": "coveredText:start:end:ontologyConceptArr",
+         "date": "2013-11-22T14:13:25Z",
+         "dc:format": "application/pdf; version=1.5",
+         "dc:title": "JW-AJH#130002 1083..1088",
+         "dcterms:created": "2013-11-20T13:24:11Z",
+         "dcterms:modified": "2013-11-22T14:13:25Z",
+         "meta:creation-date": "2013-11-20T13:24:11Z",
+         "meta:save-date": "2013-11-22T14:13:25Z",
+         "modified": "2013-11-22T14:13:25Z",
+         "pdf:PDFVersion": "1.5",
+         "pdf:encrypted": "false",
+         "producer": "PDFlib PLOP 2.0.0p6 (SunOS)/Adobe LiveCycle PDFG ES",
+         "resourceName": "Vose-2013-American_Journal_of_Hematology.pdf",
+         "title": "JW-AJH#130002 1083..1088",
+         "xmp:CreatorTool": "Arbortext Advanced Print Publisher 9.0.114/W",
+         "xmpTPg:NPages": "7"
+     }
+ ]
+ }}}
+